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ABSTRACT

The era of highly active antiretroviral therapy (HAART) has controlled AIDS and
its related disorders considerably; however, the prevalence of HIV-1-associated
neurocognitive disorders (HAND) has been on the rise in the post-HAART era. In view
of these developments, we investigated whether a HAART drug combination of 3’Azido-2’, 3’-deoxythymidine (AZT) and Indinavir (IDV) can alter the functionality of the
blood-brain barrier (BBB) endothelial cells, thereby exacerbating the condition. Viability
of hCMEC/D3 cells (in vitro model of BBB) that were exposed to the drugs was
significantly reduced after a 72 hr treatment, in a dose-dependent manner. Reactive
oxygen species (ROS) were highly elevated after the exposure, indicating that
mechanisms that induce oxidative stress were involved. Measures of oxidative stress such
as glutathione (GSH) and malondialdehyde (MDA) were found to be altered in the
treated groups. Loss of mitochondrial membrane potential (ΔΨm) assessed with
fluorescent microscopy and decreased levels of ATP indicated that cytoxicity was
mediated through mitochondrial dysfunction. Furthermore, AZT + IDV treatment caused
apoptosis in endothelial cells as assessed by the expression of cytochrome c and
procaspase-3 proteins. In vivo experiments with HIV-1 transgenic animal treated with
AZT+IDV showed decrease in GSH in the BBB and brain and increase in MDA levels in
the BBB. Thiol antioxidant N-acetylcysteine amide (NACA) reversed some of the prooxidant effects of AZT+IDV in both invitro and invivo studies.
Results from our studies indicate that the AZT + IDV combination can affect the
BBB and may play a role in contributing to neurocognitive disorders in HIV-1 infected
individuals treated with HAART drugs.
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NOMENCLATURE

ART

Antiretroviral Therapy

AZT

3’-Azido-2’, 3’-deoxythymidine

BBB

Blood-Brain Barrier

BM

Basement Membrane

CAT

Catalase

gp120

HIV-1 Envelope Glycoprotein 120

GSH

Glutathione

HIV-1

Human Immunodeficiency Virus

HAND

HIV-1- Associated Neurocognitive Disorders

HAART

Highly Active Antiretroviral Therapy

IDV

Indinavir

MDA

Malondialdehyde

NO

Nitric Oxide

PC

Pericytes

PI

Protease Inhibitors

PUFAs

Polyunsaturated Fatty Acids

Tat

Transregulatory Protein

TJ

Tight Junctions

ROS

Reactive Oxygen Species

SIV

Simian Immunodeficiency Virus

SOD

Superoxide Dismutase

1. INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) is a lentivirus (a member of
the retrovirus family) that causes acquired immunodeficiency syndrome (AIDS), a
condition in humans in which the immune system begins to fail, leading to lifethreatening opportunistic infections. HIV-1 infection has also been identified for its
ability to target the nervous tissues. Infection of the nervous system with HIV can lead to
a syndrome of neurological dysfunction currently termed as HIV-associated
neurocognitive disorders; HAND (Antinori et al., 2007). HAND is a collective term used
to denote the neurological complications of AIDS, consisting of the triad of cognitive,
behavior, and motor dysfunction (McArthur et al., 2004). HAND develops in about one
third of patients who progress to AIDS. The precise mechanisms of pathogenesis
involved in HIV induced central nervous system injury are still not completely
understood.
The blood- brain barrier (BBB), a selective interface between blood and the
central nervous system, regulates the transport of substances from blood to brain and
brain to blood (Banks et al., 2005). The disruption of this layer has been implicated in
number of neurocognitive disorders like Alzheimer’s and Parkinson’s disease (Zipser et
al., 2007; Power et al., 1993). A mild to normal grade disruption has been found in HIV
patients with neurocognitive disorders (Power et al., 1993). Recent studies have reported
that viral proteins like glyco-protein 120 (gp 120) and transregulatory (Tat) protein can
alter the endothelial function and disrupt the blood brain barrier, both in vitro and in
vivo, through an oxidative stress mediated mechanism (Price et al., 2006, Banerjee et. al.,
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2010). These alterations can play critical roles in the signaling pathways that lead to
upregulation of inflammatory genes in the BBB and accelerate neurodegeneration.
Introduction of highly active antiretroviral therapy (HAART), the combination of
two or more classes of antiretroviral drugs, has led to a considerable decline in HIV
disease progression rates and related opportunistic infections. Despite these significant
improvements in health conditions, mild cognitive impairment in HIV -infected
individuals seems to be on the rise and still remains a public health concern in the
HAART era (Sacktor et al., 2002). Recent studies have shown that neurocognition
improved significantly following discontinuation of HAART in subjects with preserved
immune function (Robertson et al., 2010). HAART regimens have been recognized as
leading to mitochondrial toxicity and are associated with cardiac, hepatic, hematologic,
and myopathic morbidity (Carr et al., 1999). Numerous mechanisms have been proposed
to explain the deleterious impact of HAART drugs, including mitochondrial DNA
depletion, impaired mitochondrial replication via inhibition of the mitochondrial DNA
polymerase gamma (POLγ), and subsequent increase in reactive oxygen species and
oxidative stress (Lewis et al., 2003).
The above discussed research, concerning the effects of HAART drugs in various
metabolic disorders raises doubt about the possible impact of antiretroviral therapy on
the BBB and neurocognition in HAART-treated HIV patients. To the best of our
knowledge, no known study has been done to evaluate the effect of HAART drugs on the
human blood-brain barrier and the mechanism involved in this effect. In order to address
this concern, we hypothesized that HAART drugs may cause endothelial dysfunction in
the BBB, thereby exacerbating HIV-1- associated neurocognitive disorders. In order to
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test our hypothesis we evaluated the effect of the combination of 3’-Azido-2’, 3’deoxythymidine (AZT), and Indinavir (IDV), (a commonly recommended HAART
regimen) on various oxidative stress parameters, as well mitochondrial dysfunction in
blood-brain barrier endothelial cells (Yeni et al., 2004). In addition to this, toxicity of
HIV proteins, HAART toxicity appears to be related through a common phenomenon of
oxidative stress. The possible involvement of oxidative stress suggests the use of
antioxidants in suppressing harmful effects and protecting the BBB. Recently, a new low
molecular thiol antioxidant, N-acetylcysteine amide (NACA), with the ability to cross the
BBB has been effective in protecting cells from viral proteins in in vitro and in vivo
studies in our lab (Price et.al., 2006). So we investigated the role of oxidative stress in
viral proteins and HAART drugs induced toxicity in the BBB of HIV-1 transgenic mice.
Concomitantly, we explored the antioxidant effect of NACA in reversing the oxidative
stress related effects induced by viral proteins and HAART drugs on the BBB.
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2. REVIEW OF LITERATURE
2.1. GLOBAL STATISTICS ON HIV
In 1981, the first cases of acquired immunodeficiency syndrome (AIDS) were
reported to the Centers for Disease Control and Prevention (CDC). Since that time, the
HIV epidemic has expanded to become one of the greatest public health challenges, both
nationally and globally. There are estimated to be around 33.2 million people living with
HIV or AIDS worldwide today and around 2.5 million more people are newly infected
with HIV every year. Of the 2.5 million people newly infected with HIV each year, 50%
of them are under the age of 25 years. Around 22.5 million people who are currently
infected with HIV or AIDS are living in Africa, and more than one million people were
living with AIDS in USA. A total of 25 million people have died from AIDS since the
year 1981 and it is estimated that more than half a million have died in the U.S alone
(Woods et al., 2009).
2.2. STRUCTURE OF HIV
HIV is an enveloped RNA virus whose basic structure consists of an outer bilayer
of lipid and glycoprotein and an inner core containing two single RNA strands bound
together by a gag-derived protein, p24. The outer membrane of HIV contains specific
structural elements that play important roles in infectivity and disease progression. The
most important of these is the viral envelope glycoprotein 120 (gp120), which is
necessary for HIV’s interaction with host cell receptors on cells, including CD4+
lymphocytes, macrophages, and monocytes. Gp120 is closely associated with the
envelope transmembrane viral protein, gp41, which is involved in viral–cell membrane
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fusion. Both gp41 and gp120 are essential for infectivity. Gp120 interacts with the CD4+
receptor on the surface of susceptible cells. However, gp120 attachment also requires the
presence of chemokine co-receptors, such as CXCR4 or CCR5, which facilitate the
process of cell binding and entry (Gonda, 1988).
2.3. HIV-1-ASSOCIATED NEUROCOGNTIVE DISORDERS (HAND)
HIV enters the CNS early in the course of infection, and the virus resides
primarily in microglia and macrophages. However, infection of these cells may not be
sufficient to initiate neurodegeneration (Gartner et al., 2000). It has been proposed that
factors associated with advanced HIV infection in the periphery (non-CNS) are important
triggers for events leading to neurocognitive disorders (Kaul et al., 2001). The clinical
manifestations of CNS disorders in HIV/AIDS include depression and all degrees of
cognitive impairment collectively termed as HIV-1-associated neurocognitive disorder
(HAND). HAND is characterized by a triad of cognitive, behavioral, and motor
dysfunctions (McArthur, 2004). For milder forms of HAND, difficulties in concentration,
attention, and memory may be present although the neurologic examination is
unremarkable. Affected individuals are easily distracted, lose their train of thought, and
require repeated prompting. Activities of daily living may take longer and become more
laborious.
More severe forms of HAND, such as HIV- associated dementia, are seen in
untreated HIV individuals. Cognitive and motor dysfunctions are more pronounced in
these individuals, and the assistance of a caregiver is required to maintain activities of
daily living. The most commonly observed symptoms include delayed speech output with
long pauses between words, poor thought and emotional content characterized by lack of
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spontaneity, and social withdrawal that is often mistakenly diagnosed as severe
depression. Gait abnormalities and a reduction in motor movements are observed (Woods
et al., 2009).
To date, the four possible mechanisms that are supportive of viral entry into the
CNS and are currently under investigation include: the transmission of virus in infected
macrophages (the Trojan horse model), direct infection of the blood-brain barrier (BBB)
by HIV; transcytosis of HIV; and BBB disruption (Piacentini et al., 2005). This neuro
invasion in turn elicits a series of neuroinflammatory responses, resulting in neurologic
dysfunctions in a significant number of individuals with AIDS. This is characterized by
BBB disruption, leukocyte infiltration into the CNS, formation of microglia nodules and
multinucleated giant cells, astrocyte activation and eventual damage and/or loss of
neurons (Xu et al., 2005). To date the mechanisms leading to HAND in AIDS patients are
not fully understood; however, it is thought that activated macrophage, microglia, and
astrocytes produce chemokines and cytokines that in conjunction with secreted viral
proteins may damage the BBB and leading to increased permeability and neuronal
demise (Giulian et al., 1990; Bellizzi et al., 2006; Rumbaugh and Nath, 2006).
2.4. BLOOD-BRAIN BARRIER
The BBB is crucial in HIV infection of the CNS (Gartener et al., 2000). The BBB
is an endothelial barrier present in capillaries that innervate the brain. The BBB is
selective barrier which impedes entry from the blood to the brain of virtually all
molecules, except those that are small and lipophilic. The BBB endothelial cells differ
from endothelial cells in the rest of the body by the absence of fenestrations, more
extensive tight junctions (TJs), and sparse pinocytic vesicular transport. Endothelial cell
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tight junctions limit the paracellular flux of hydrophilic molecules across the BBB. In
contrast, small lipophilic substances such as O2 and CO2 diffuse freely across plasma
membranes along their concentration gradient (Grieb et al., 1985). Nutrients including
glucose and amino acids enter the brain via transporters, whereas receptor-mediated
endocytosis mediates the uptake of larger molecules including insulin, leptin, and iron
transferrin (Pardridge et al., 1985; Zhang et al., 2001). In addition to endothelial cells, the
BBB is composed of the capillary basement membrane (BM), astrocyte end-feet
ensheathing the vessels and pericytes (PCs) embedded within the BM. The TJ consists of
three integral membrane proteins, namely, claudin, occludin, and junction adhesion
molecules, and a number of cytoplasmic accessory proteins including ZO-1, ZO-2, ZO-3,
cingulin, and others. Claudins-1 and -2 are 22 kDa phosphoprotein and have four
transmembrane domains. Claudins bind to claudins on adjacent endothelial cells to form
a primary seal of the TJ (Furuse et al., 1999). A carboxy terminal of claudins binds to
cytoplasmic proteins including ZO-1, ZO-2, and ZO-3. Occludin is a 65-kDa
phosphoprotein, significantly larger than claudin. Occludin has four transmembrane
domains, a long COOH-terminal cytoplasmic domain, and a short NH2-terminal
cytoplasmic domain. The two extracellular loops of occludin and claudin, originating
from neighboring cells, form the paracellular barrier of TJ. The cytoplasmic domain of
occludin is directly associated with ZO protein. Cytoplasmic proteins involved in TJ
formation include zonula occludens proteins (ZO-1, ZO-2, and ZO-3), cingulin, 7H6, and
several others. Importantly, actin, the primary cytoskeleton protein, binds to COOHterminal of ZO-1 and ZO-2, and this complex cross-links transmembrane elements and
thus provides structural support to the endothelial cells. In pathologic conditions, a
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number of chemical mediators are released that increase BBB permeability. Several of
these mediators of BBB opening have been studied in both in vivo and in vitro
experiments and include glutamate, aspartate, taurine, ATP, endothelin-1, NO, MIP-2,
tumor necrosis factor-a (TNF-α), and IL-β, which are produced by astrocytes . Other
agents reported to increase BBB permeability are bradykinin, 5HT, histamine, thrombin,
UTP, UMP, substance P, quinolinic acid, platelet activating factor, and free radicals
(Abbott, 2002; Annunziata et al., 1998; Pan et al., 2001; Stastny et al., 2000).

Figure 2.1. Schematic representation of protein interactions at tight junctions

Histological studies of specimens from HIV-1-infected humans and simian
immunodeficiency virus (SIV)-infected rhesus macaques show that lymphocytes and
monocytes migrate into the brain (Prospero-Garcia et al., 1996; Kalams et.al., 1995).
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However, the relevance of CNS-invading lymphocytes in HAND is not clear. It has also
been suggested that the inflammatory cytokine tumour-necrosis factor-a (TNF-) opens a
paracellular route for HIV-1 across the BBB (Fiala et al., 1997). These findings indicate
that one reason why HAND rarely occurs before the onset of advanced HIV disease is
that a scathing cycle of immune dysregulation and BBB dysfunction is required to
achieve sufficient entry of infected or activated immune cells into the brain to cause
neuronal injury. Alterations of the BBB have been observed in transgenic mice
expressing the HIV envelope protein gp120 in a form that circulates in plasma,
suggesting that circulating virus or envelope proteins may also cause BBB dysfunction
during the viremic phase of primary infection (Toneatto et al., 1999).
2.5. OXIDATIVE STRESS IN BBB DYSFUNCTION
Free radicals are compounds possessing an unpaired electron, which renders them
highly reactive and capable of causing oxidative damage to all the major macromolecules in cells, including lipids, proteins and nucleic acids (Zoccal et al., 2000). A
major family of free radicals is the reactive oxygen species (ROS), derived metabolically
from molecular oxygen via superoxide anions (O2-). Oxidative attack on proteins results
in the formation of protein carbonyls, often with the loss of functionality of the parent
protein. Polyunsaturated fatty acids, which are major components of cell membranes, can
also undergo free radical attack, producing lipid peroxidation products like
malondialdehyde (MDA) and 4-hydroxynonenal (Halliwell et al., 1997). Under normal
circumstances, the body is protected from such damage by a careful balance between prooxidants and cellular antioxidants like glutathione. Any imbalance between the prooxidants and antioxidants results in a condition called oxidative stress.
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Under physiological conditions, the integrity of the BBB is shielded from
oxidative stress because the brain endothelial cells have high cellular levels of
antioxidants such as GSH, superoxide dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GPx). These enzymes protect the cells from free radicals and peroxidative
damage (Price et al., 2006). On the other hand, BBB is highly susceptible to oxidative
damage due to the presence of poly unsaturated fatty acids (PUFA’s). These fatty acids
are easily peroxidizable leading to lipid peroxidation metabolites like MDA. Free radical
production and the resulting oxidative stress, along with circulating inflammatory
chemokines, play a key role in HAND (Agarwal et. al., 1999).
Viral proteins, gp 120 and Tat have been shown to cause oxidative stress in
endothelial cells. The mechanism by which HIV-1 proteins induce oxidative stress is not
completely known. One proposed mechanism is that HIV-1 induced neurotoxicity may be
due to an increased production of ROS by HIV-1 proteins (gp120 and Tat). The
pathogenesis of HIV-1 infection has implicated increased levels of ROS. HIV-infected
individuals have abnormally low levels of antioxidants, such as glutathione (GSH), the
major intracellular defense against the production of ROS. Additionally, a reduction in
GSH levels, accompanied by elevated levels of malondialdehyde (MDA), a reflection of
increased levels of lipid peroxidation, has been reported in HIV-1 infected patients
(Sonneberg et al., 1988).
The HIV-1 envelope glycoprotein (gp120) and transregulatory protein (Tat) of
HIV-1 are neurotoxic and cytotoxic and have been implicated in the development of
HAND. They are known to cause oxidative stress and have been associated with
disruption of the BBB (Annuziata et al., 2003). Recently, it has been shown that there is
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some evidence that binding of gp120 or Tat protein to brain endothelial cells may cause
many of the changes seen in the BBB. For example, one study found a significant
increase in permeability (up to 47%) in cultured endothelial cells after exposure to gp120
(Cioni et al., 2002). Another study confirmed that gp120 is capable of changing and
activating the vascular component of the BBB in vivo (Tonneato et al., 1999). Another
study of HIV-1 Tat protein demonstrated that exposure of endothelial cells to HIV-1 Tat
protein resulted in a dose-dependent increase in oxidative stress and a decrease in
intracellular GSH (Toborek et al., 2003). GSH, which is an important intracellular nonprotein thiol compound in the mammalian cells, has a pivotal role in the maintenance of
membrane integrity. It may also play an important role in the proper functioning of the
BBB (Agarwal et. al., 1999). Although brain endothelial cells possess high intracellular
levels of antioxidative defense mechanisms, such as GSH, GSH peroxidase, and catalase,
exposure to toxins and drugs may render the BBB susceptible to toxic damage and alter
its specific functions.
Both gp120 and Tat are able to induce apoptosis of cultured neurons and can
render neurons vulnerable to excitoxicity and oxidative stress (Corasaniti et al, 2001).
Other viral proteins, Nef, Vpr, and protease, are also suggested as sources of oxidative
stress, as well as being disruptive and causing change in the mitochondrial
transmembrane potential (Aksenova et al., 2005). Most researchers believe that the least
instigation of apoptosis by oxidative stress is during HAND, although other factors may
also play key or supportive roles. Pro-apoptotic conditions related to oxidative stress
include: depletion of Bcl-2, (an anti-apoptotic/antioxidant protein), decrease in apoptosis
in cells infected with HIV (even though antioxidants are provided), and secretion of pro-
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apoptotic/pro-oxidant cytokines (molecular signalers) from macrophages (Lipton et al.,
1995)
It has been found that the death of neurons in a rat cortex neuronal culture,
mediated by gp120, was due to nitric oxide (NO) production (Dawson et al., 1993). NO,
which is synthesized by vascular endothelial cells, is a very strong vasodilatory
substance. NO also helps to modulate signaling in intercellular and intracellular
communication for BBB permeability. In addition, NO regulates ion channels in cells,
neurotransmissions, and cytotoxicity. NO may not be the only toxin, or even the only free
radical, associated with HAND. Vague schematics of general pathways for infection are
proposed, however. It is commonly thought that gp120 plays a role in the infection of the
BBB’s endothelial cells, creating an environment in which there is greater nitric oxide
synthase (NOS) production. Once the NOS produces more NO, the NO could cause the
breakdown of the BBB’s endothelial cells, rendering it ineffective in its usual functions
(Dawson et al., 1993). Previous research has also demonstrated that oxidative stress was
induced in brain endothelial cells in vitro and in vivo, when exposed to the HIV-1
proteins gp 120 and Tat protein depleted intracellular GSH, increased lipid peroxidation,
and reduced antioxidant enzyme levels (catalase, GPx, glutathione reductase). CD-1
mice, injected with these proteins (gp120 + Tat) also decreased the expression of tight
junction proteins ZO-1, ZO-2, Occludin, and Claudin-5 (Banerjee et al., 2010).
2.6. HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
During the last twenty years, major progress has been made in the understanding
and treatment of human immunodeficiency virus (HIV) infection. Different classes of
antiretroviral agents are approved for the treatment of HIV-infection (Table 2.1). These
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substances could be divided into three classes, based on their mechanisms of action
(Clercq et al., 2005).
Reverse transcriptase inhibitors (RTIs): This class of drugs targets construction of viral
DNA by inhibiting activity of reverse transcriptase. There are two subtypes of RTIs with
different mechanisms of action: nucleoside-analogue RTIs (NRTIs) are incorporated into
the viral DNA leading to chain termination, while non-nucleoside-analogue RTIs
(NNRTIs) distort the binding potential of the reverse transcriptase enzyme. RTIs come in
three forms:


Nucleoside analog reverse transcriptase inhibitors (NARTIs or NRTIs)



Nucleotide analog reverse transcriptase inhibitors (NtARTIs or NtRTIs)



Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
The mode of action of NRTIs and NtRTIs is essentially the same; they are

analogues of the naturally occurring deoxynucleotides needed to synthesize the viral
DNA and they compete with the natural deoxynucleotides for incorporation into the
growing viral DNA chain. However, unlike the natural deoxynucleotides substrates,
NRTIs and NtRTIs lack a 3'-hydroxyl group on the deoxyribose moiety. As a result,
following incorporation of an NRTI or an NtRTI, the next incoming deoxynucleotide
cannot form the next 5'-3' phosphodiester bond needed to extend the DNA chain. Thus,
when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted, a process known
as chain termination (Jochmans et al., 2008). All NRTIs and NtRTIs are classified
as competitive substrate inhibitors. In contrast; NNRTIs have a completely different
mode of action. NNRTIs block reverse transcriptase by binding at a different site on the
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enzyme, compared to NRTIs and NtRTIs. NNRTIs are not incorporated into the viral
DNA but instead inhibit the movement of protein domains of reverse transcriptase that
are needed to carry out the process of DNA synthesis. NNRTIs are therefore classified
as non-competitive inhibitors of reverse transcriptase.
Protease inhibitors (PIs): HIV-1 protease is a complex enzyme composed of two
identical halves (ie, a symmetrical dimer) with an active site located at the base of the
cleft. It is responsible for the cleavage of the large viral precursor polypeptide chains into
smaller, functional proteins, thus allowing maturation of the HIV virion. This process
takes place in the final stages of the HIV life cycle. Inhibition of the protease enzyme
results in the release of structurally disorganized and noninfectious viral particles.
Protease inhibitors target viral assembly by inhibiting the activity of protease, an enzyme
used by HIV to cleave nascent proteins for final assembly of new virons. HIV PI’s target
the peptide linkages in the gag and gag-pol polyproteins which must be cleaved by
protease (Monini et al., 2003). All approved PI’s contain a hydroxyethylene bond instead
of a normal peptide bond. The hydroxyethylene bond makes PI’s non-scissile substrate
analogs for HIV protease (Figure 2.2). There are 10 PIs currently approved for clinical
use. Drug interactions are important considerations with the use of PIs. Protease
inhibitors are substrates for the cytochrome P450 system (primarily CYP3A4) and are
themselves, to varying degrees, inhibitors of this system, with ritonavir being the most
potent inhibitor.
Some PIs, such as lopinavir and tipranavir, are also inducers of CYP3A4. This
leads to a significant number of interactions with drugs that are inducers, inhibitors, or
substrates of this system (Block et al., 2004).
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Fusion inhibitors: These drugs block HIV from fusing with a cell's membrane to enter
and infect it.

Table 2.1. Approved HAART drugs
Protease

NRTIs

NNRTIs

Mixed Class

Mprenavir

Abacavir

Delavirdine

enfuvirtide ( fusion inhibitor)

Atazanavir

Didanosine (ddI)

Efavirenz

maraviroc (CCR5 antagonist)

Darunavir

Emtricitabine (FTC)

Etravirine

raltegravir (integrase inhibitor)

Fosamprenavir

Lamivudine (3TC)

Nevirapine

Indinavir

Stavudine (d4T)

Delavirdine

Lopinavir/ritonavir

Zidovudine (AZT)

Nelfinavir

Zalcitabine (ddC)

Inhibitors

Integrase inhibitors: These drugs inhibit the enzyme integrase, which is responsible for
integration of viral DNA into the DNA of the infected cell. There are several integrase
inhibitors currently under clinical trial but none are commercially available.
Current national guidelines for antiretroviral therapy recommend the use of
combinations of different classes of antiretroviral agents. These therapeutic regimes,
called highly active antiretroviral therapy (HAART), usually consist of 2 NRTIs
combined with a PI or a NNRTI (Clercq et al., 2005). Alternative regimes include 3
NRTIs. HAART is now the standard of care for HIV-therapy and has led to substantial
reduction in morbidity and near-complete suppression of HIV-1 replication.
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Figure 2.2. Mechanism of action of protease inhibitors.

Since HAART is unlikely to eradicate HIV-1, antiviral therapy may be required
for a lifetime, leading to an increase in attention on the long term safety of HAART.
Previously, according to the International U.S. AIDS Panel, no known adverse effects
have been reported in patients treated with a combination of 3’-azido-2’, 3’deoxythymidine (AZT or Zidovudine), and indinavir (IDV) -one of the most common
therapeutic regimens recommended in HAART (Yeni et al., 2004). AZT belongs to the
class of NRTIs, and structurally resembles a thymidine (a nucleoside analog) whereas
IDV belongs to protease inhibitor family (Figure 2.3). However, several toxicities related
to these drugs have been recently reported. As the AZT+IDV combination is one of the
common regimens in HAART, our current study was performed utilizing a combination
of these drugs to study their effects on BBB endothelial cells.
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(A)

(B)

Figure 2.3. Structure of (A) 3’-azido-2’, 3’-deoxythymidine (B) Indinavir.

2.7. NEUROCOGNITIVE DISORDERS IN HAART ERA
Since its introduction in 1996, HAART has drastically improved the life
expectancy of those living with HIV. Antiretroviral therapy has led to long-term survival
for HIV-infected individuals. Thus, the number of HIV-infected persons has increased
along with the proportion of those who are considered “older”. While the incidence of a
severe form of HAND appears to have decreased since the introduction of HAART, the
prevalence of HAND appears to be on the rise. Unfortunately, it is not at all clear that
HAART provides long-term protection from HAND. In recent years, the incidence of
HAND as an AIDS-defining illness has actually increased and recent studies have
estimated that the prevalence of HAND is unchanged or escalating, even in populations
with extensive use of HAART. The proportion of new cases of HAND demonstrating a
CD4 count greater than 200 is also increasing in HAART patients (Sacktor et al 2001).
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The associated toxicity of long-term antiretroviral therapy includes the risk of
developing central obesity, dyslipidemia, and insulin resistance (Behrens et al., 1999). It
is well known that vascular endothelial dysfunction is a common phenomenon in
HAART- treated patients, and this known association between these vascular risk factors
and dementia, suggests that long-term HAART use may actually contribute to the risk of
acquiring HAND (Whitmer et al. 2005). Metabolic derangement observed in HAARTtreated patients that might contribute to HAND risk is the effect of nucleoside reverse
transcriptase inhibitors (NRTIs) on mitochondria. HAART regimens that include NRTIs
like AZT have been recognized as leading to mitochondrial toxicity and are associated
with cardiac, hepatic, hematologic, and myopathic morbidity (Lewis and Dalakas 1995).
Numerous mechanisms have been proposed to explain the deleterious impact of
NRTIs, including mitochondrial depletion, impaired mitochondrial replication via
inhibition of the mitochondrial DNA polymerase gamma (POLγ), and subsequent
increase in ROS (Lewis et al., 2003). POLγ-independent mechanisms of impairing
mitochondrial function have also been implicated, including decreased mitochondrial
DNA transcription protein glycosylation, and altered expression of lipid metabolism
genes (Mallon et al., 2005). Mitochondrial dysfunction is a feature of a number of
neurodegenerative diseases, including AD, Parkinson’s disease, amyotrophic lateral
sclerosis, and Huntington’s disease (Knott et al., 2008; Lin and Beal, 2006). Evidence of
oxidative stress in the CNS has also been demonstrated in patients with HAND (Turchan
et al., 2003). Proton magnetic resonance spectroscopy illustrates mitochondrial
dysfunction in patients taking an NRTI as a component of HAART therapy. Nacetylaspartate levels, a marker of neuronal mitochondrial integrity, are lower in frontal
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white matter in HIV+ patients taking the NRTIs didanosine or stavudine as compared to
those who are HIV- or HIV+ on alternative antiretroviral therapy (Schweinsburg et al.
2005). Additional evidence that NRTI exposure might cause neuronal injury by inducing
mitochondrial toxicity comes from an investigation of synaptosomes and brain
mitochondria treated with the NRTI, 2′, 3′-dideoxycytidine (ddC). This treatment led to
cytochrome c release, decreased expression of the antiapoptotic molecule Bcl-2, and
increased protein levels of the proapoptotic molecules caspase-3 and Bax, highlighting
direct pathways between NRTI therapy and neuronal cell death and dysfunction (Opii et
al., 2007)
Another class of drugs primarily involved in HAART treatment includes protease
inhibitors like indinavir that have been associated with several toxicities. The deleterious
effects of HIV protease inhibitors have been associated with ROS overproduction and
also endoplasmic reticulum stress, but the relation between these two events is not
known. In human aortic endothelial cells, protease inhibitors alone and as part of
HAART regimens increase ROS production (Jiang et al., 2007). Nelfinavir induces
oxidative stress and can also lead to adipocyte necrosis (Vincent et al., 2004) and
premature senescence in human fibroblasts (Caron et al., 2007). In addition, production
of nitric oxide, a mediator of protein nitrosylation, and other ROS that alter cellular
redox-dependent reactions interferes with protein disulphide bonding and results in
misfolding of proteins that accumulate in endoplasmic reticulum lumen. Treatment of
peripheral blood mononuclear cells from healthy donors with a higher concentration (10
µM) of an HIV protease inhibitor, saquinavir or indinavir, has induced both a loss in
mitochondrial membrane potential (ΔΨm) and cell death (Estaquier et al., 2002).
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Although the exact mechanism still eludes researchers, it is being established that
protease inhibitors may have the potential for both beneficial and detrimental effects on
human cells independent of their antiretroviral effects.
2.8. ROLE OF N-ACETYLCYSTEINE AMIDE (NACA)
Glutathione (GSH) and other sulfhydryl-containing compounds are found to be
decreased in HIV- infected patients’ blood, liver, and cerebro spinal fluid samples.
Although life expectancy is very poor for these patients, if given GSH, life expectency
significantly increases. The roles of GSH in the brain are to protect neurons against ROS
and its stable byproducts, such as hydroxynonenal (Pocernich et al., 2005). GSH is also
responsible for maintaining redox balance in the brain endothelial cells, thereby
protecting them from oxidative stress (Toborek et al., 2005), as well as playing a crucial
role in maintaining the BBB’s normal functions (Agarwal et al., 1999). As a result, the
compounds that increase intracellular GSH such as N-acetylcysteine (NAC), GSH ethyl
ester, and GSH, are becoming increasingly popular for treating oxidative stress-related
disorders. GSH is the principal intracellular thiol responsible for scavenging ROS and
maintaining the oxidative balance in tissues. Cysteine (Cys) and glutathione delivery
compounds have been used to protect normal cells from redox imbalance. Therefore,
thiol-containing compounds gained special attention due to their profound role in
maintaining tissue redox balance. One of the most widely used thiol antioxidants has
been NAC (Holdiness et al., 1991). NAC, the drug of choice in acetaminophen (Tylenol)
intoxication, indirectly replenished GSH through deacetylation to cysteine, preventing
oxidative damage through scavenging of ROS (Cotgreave et al., 1997). It has been shown
that it protects cells from radiation-induced damage (Neal et al., 2003).
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NAC was suggested as a therapeutic in HIV-1 infected patients, after the
discovery of its effect on the inhibition of virus replication in lymphocytes (Staal et al.,
1990). HIV-1 infected patients showed a decrease in GSH and Cys levels; therefore, it
seemed to be a logical solution to replenish GSH and Cys by NAC (Droge et al., 1992).
Oral NAC increased the intracellular GSH levels, decreased the mortality rate of patients,
and prevented the loss of CD4+ T cells. Recently, NAC analogs have been introduced as
an additional regimen for the treatment of HIV infection (Oiry et al., 2004). However,
NAC has numerous side effects, including being pro-oxidant, suppressing respiratory
burst, and causing a toxic ammonia accumulation in case of liver problems (Cotgreave et
al., 1997). Moreover, NAC’s failure to provide significant antioxidant effects in vivo,
may be due to its low solubility and tissue distribution (Atlas et al., 1999). A new strategy
has recently been introduced for improving the pharmacokinetic properties of these
agents. This was achieved by neutralizing the carboxylic group of NAC, which made the
drug more lipophilic and cell-permeating (Figure 2.3B). This compound was shown to
cross the BBB, scavenge free radicals, chelate copper, and attenuate myelin
oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune
encephalomyelitis in a multiple sclerosis mouse model (Offen et al., 2004). Further
evidence of the efficient membrane permeation of NACA was demonstrated in a recent
study which assessed NACA for its antioxidant and protective effects in a model using
human red blood cells (Grinberg et al., 2005). NACA has been used as a potential
neuroprotective drug in an animal model of Parkinson’s disease, where it reduces
neurodegeneration and progression of the disease. NACA passes through the BBB and
protects the dopaminergic neurons against ROS in in vivo and in vitro models (Bahat et
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al., 2005). NACA and two other newly synthesized thiols (N-acetyl-gly-cys-amide and
N-acetyl-Cys-Gly-Pro-Cys-amide) eliminate β amyloid-induced oxidative stress and
neurotoxicity in vitro (Bartov et al., 2006). It has been suggested that NACA and the
other aforementioned thiols cross the BBB and scavenge the free radicals directly or
indirectly by providing Cys and GSH.
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Figure. 2.3. Structures of (A) NAC and (B) NACA. The carboxyl group has been
replaced by amide in NACA.

Recent studies have also investigated the ability of NACA to protect in vitro and
in vivo from HIV proteins, diesel exhaust particles that induced oxidative stress, and
toxicity (Banerjee et al., 2010; 2009). Studies from our lab have also reported that NACA
had greater free radical scavenging abilities and reducing powers than NAC (Ates et al.,
2008).
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3. EXPERIMENTAL DESIGN
3.1. MATERIALS AND METHODS
3.1.1. Materials. N-(1-pyrenyl)-maleimide (NPM) was purchased from Sigma
(St. Louis, MO). N-acetylcysteine amide was provided by Dr. Glenn Goldstein (David
Pharmaceuticals, NewYork, NY, USA). High-performance liquid chromatography
(HPLC) grade solvents were purchased from Fisher Scientific (Fair Lawn, NJ). AZT and
IDV were a gift from the National Institutes of Health AIDS Research and Reference
Reagent Program. JC-1 dye (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylben- zimidazolyl
carbocyanine iodide) and Fura-2AM were purchased from Invitrogen (San Diego, CA).
Calcein AM was purchased from Biotium, Inc, CA. All other chemicals were purchased
from Sigma (St. Louis, MO), unless stated otherwise.
3.1.2. Culture of Human Brain Microvascular Endothelial Cells
(hCMEC/D3). As an in vitro BBB model, immortalized human brain endothelial cells,
hCMEC/D3 (a gift from Dr. Pierre Couraud), were plated on 25 cm2 tissue culture flasks
and maintained in EBM-2 medium in humidified 5% CO2/95% air at 37 °C. The culture
medium was changed twice a week and endothelial cells at passages 28–34 were used in
this study. A serum-free and growth-factor-free medium was used in the experiments. All
assays were performed in triplicate and each experiment was repeated three times. The
EBM-2 medium (Lonza, Walkersville, MD), was supplemented with VEGF, IGF-1, EGF,
basic FGF, hydrocortisone, ascorbate, gentamycin and 2.5% fetal bovine serum (FBS), as
recommended by the manufacturer.
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3.1.3. Cytotoxicity Assay. hCMEC/D3 cells were seeded in a 96-well plate, at
densities of approximately 8x103 cells per well, and were allowed to attach for 24 hr.
The media was then discarded, and the cells were treated with AZT + IDV combination
for 24 hr and 72 hr in a serum-free media. For NACA cytotoxicity studies, the cells were
incubated with various concentrations of NACA for 24 h. Protective effects of NACA
were studied by first preincubating cells with NACA for 1 hr and were treated with
AZT+ IDV for the required time period. After the treatment, the cells were washed three
times with phosphate buffered saline (PBS), and 100 μl of 0.4 µM Calcein AM (Biotium
Inc.) in PBS was added to each well for 30 min at 37 °C. The fluorescence was measured
with an excitation wavelength at 485 nm and an emission wavelength of 530 nm, using a
microplate reader (Fluostar, BMG Labtechnologies, Durham, NC, USA).
3.1.4. Morphological Assessment of hCMEC/D3 cells. Treated hCMEC/D3
cells were assessed for their changes in cellular morphology. An Olympus inverted
microscope (model CKX1SF) with 20X objective was utilized to observe the changes in
their morphology.
3.1.5. Reactive Oxygen Species (ROS) Measurement. Intracellular ROS
generation was measured using a well characterized probe, 2′,7′-dichlorofluorescein
diacetate (DCFH2-DA) (Wang et al., 1999). DCFH2-DA is hydrolyzed by esterases to
dichloro -fluorescein (DCFH2), which is trapped within the cell. This nonfluorescent
molecule is then oxidized to fluorescent dichlorofluorescein (DCF) by the action of
cellular oxidants. The cells were exposed to the drugs for 48 hr. In order to assess the
effect of NACA on ROS levels in 100 µM AZT+IDV treated groups, cells were exposed
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to 2 mM of NACA for 1 hr before the treatment. A DCFH2-DA stock solution (in
DMSO) of 1mg/ml was diluted in serum-free media to yield a 100 μM working solution.
Cells were washed twice with PBS and then incubated with a DCFH2-DA working
solution for half an hour in a dark environment (37 °C incubator). The cells were washed
with PBS and then fluorescence was measured using a microplate reader.
3.1.6. Determination of Glutathione (GSH) Levels. The level of GSH in the
cells was determined by RP-HPLC, according to the method developed in our laboratory
(Winters et al., 1995). The HPLC system (Thermo Electron Corporation) consisted of a
Finnigan Spectra System vacuum membrane degasser (model SCM1000), a gradient
pump (model P2000), autosampler (model AS3000), and a fluorescence detector (model
FL3000) with λex=330 nm and λem=376 nm. The HPLC column used was a Reliasil
ODS-1 C18 column (5-µm packing material) with 250×4.6 mm i.d (Column Engineering,
Ontario, CA). The mobile phase (70% acetonitrile and 30% water) was adjusted to a pH
of 2 with acetic acid and o-phosphoric acid. The NPM derivatives of GSH were eluted
from the column isocratically at a flow rate of 1 ml/min. The cell pellets obtained were
homogenized in 1 ml of serine borate buffer (SBB,100 mM Tris buffer containing 10 mM
borate and 5 mM serine with 1 mM diethylene triaminepentacetic acid; pH=7.4),
centrifuged, and 250 µl of the supernatant were added to 750 µl of 1 mM NPM. The
resulting solution was incubated at room temperature for 5 min, and the reaction was
stopped by adding 10 µl of 2N HCl. The samples were then filtered through a 0.45 µm
filter and injected into the HPLC system.
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3.1.7. Determination of Malondialdehyde (MDA). The MDA levels were
determined according to the method described elsewhere (Draper et al., 1993). Briefly,
550 μl of 5% trichloroacetic acid (TCA) and 100 μl of 500 ppm butylated hydroxytoluene
(BHT) in methanol were added to 350 μl of the cell homogenates, and boiled for 30 min
in a water bath. After cooling on ice, the mixtures were centrifuged, and the supernatant
was collected and mixed 1:1 with saturated thiobarbituric acid (TBA). The mixture was
again heated in a water bath for 30 min, followed by cooling on ice. 500 μl of the mixture
were extracted with 1 ml of n-butanol and centrifuged to facilitate the separation of
phases. The resulting organic layers were first filtered through 0.45 μm filters and then
injected into the HPLC system (Shimadzu, US), which consisted of a pump (model LC6A), a Rheodyne injection valve and a fluorescence detector (model RF 535). The
column was a 100 × 4.6 mm i.d C18 column (3 µm packing material, Astec, Bellefonte,
PA). The mobile phase used contained 69.4% sodium phosphate buffer, 30% acetonitrile,
and 0.6% tetrahydrofuran. The fluorescent product was monitored at λex= 515 nm and
λem= 550 nm. Malondialdehyde bis (dimethyl acetal), which gives malondialdehyde on
acid treatment, was used as a standard.
3.1.8. Mitochondrial Membrane Potential (ΔΨm). Mitochondrial membrane
potential was determined using potentiometric fluorescent dye JC-1 (5,5′,6,6′tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl carbocyanine iodide; Invitrogen, San
Diego, CA, USA). hCMEC/D3 cells were cultured in glass bottom petri dishes and were
treated with AZT + IDV (50 µM, 100 µM , 200 µM) for 72 hr. The cells were washed
twice with PBS and then incubated with JC-1 dye (1 µg/ 1 ml) in media for 30 min. The
cells were then washed and placed under a fluorescent microscope in phenol red free
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media. The stained cells were observed with an Olympus IX51 inverted microscope at
600× total magnification with a UPLFLN 60 X NA 1.25 objective. FITC (EX 482/35
506DM EM536/40) and TexasRed (EX 562/40 593DM EM 692/40) filters were used
(Brightline). Images were captured with a Hamamatsu ORCA285 CCD camera. The
shutters, filters and camera were controlled using SlideBook software (Intelligent
Imaging Innovations, Denver, CO).
3.1.9. Measurement of ATP Levels. Total ATP was quantified using a
commercially available luciferin–luciferase assay kit (ENLITEN ATP assay kit,
Promega, WI). A series of dilutions ranging from 0 to 1x10-13 M of the ATP stock
standard were made using ATP free water supplied in the kit. Using sterile disposable
tips, 100 µl aliquots of standards were pipetted into a clean 96-well microplate.
Additionally, 100 µl of cell lysate containing an equal amount of protein was placed into
the 96 well microplate. Once all of the standards and samples were pipetted, 100 µl
aliquots of luciferin–luciferase mixture from the ATP assay kit were dispensed into the
wells. Luminescence was measured after 15 min at 37°C using a luminometer (Fluostar,
BMG Labtechnologies, Durham, NC, USA). The mean value of the luminescence was
calculated for each treatment and plotted.
3.1.10. Catalase Activity. The activity of catalase (CAT; EC 1.11.1.6) was
measured spectrophotometrically at 240 nm, following the exponential disappearance of
hydrogen peroxide (H2O2; 10 mM), according to the method describe elsewhere (aebi,
1984). Cell pellets were homogenized in phosphate buffer (50 mM, pH 7.4) containing 1
mM EDTA and centrifuged at 8500 g for 10 min. An appropriate volume of supernatant
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was mixed with phosphate buffer (50 mM, pH 7.0) and the reaction was initiated by
adding a H2O2 solution. The decrease in absorbance at 240 nm was measured for 2 min.
The catalase activity was calculated using ΔA240/min from the initial linear portion of
the curve and expressed as units/mg protein. One unit is defined as the amount of enzyme
that decomposes one micromole of H2O2 per minute under specified conditions of
temperature and pH (25 °C; pH 7.0).
3.1.11. Western Blot Analysis. Cell homogenates were prepared in a lysis buffer
(0.5% triton-x-100, 50 mM NaCl, 10 mM Tris, 1 mM EDTA, 1 mM EGTA, 2 mM
sodium vanadate, 0.2 mM PMSF, 1 mM HEPES, 1 μg/ml leupeptin, and 1 μg/ml
aprotinin). The cytosolic extracts were cleared by centrifugation at 12,000 xg for 15 min
at 4°C, and the protein concentration was estimated using a Bio-Rad 250 protein assay kit
(Bio-Rad, Hercules, CA). Protein samples (40 μg) were resolved by electrophoresis on a
12% sodium dodecyl sulfate (SDS) polyacrylamide gel (120v, 1.5 hr) in a running gel
buffer containing 25 mM Tris, pH 8.3, 162 mM glycine, and 0.1% SDS. The samples
were transferred to nylon membrane for 1 hr and 20 min at 350 mA. The membranes
were incubated overnight in a mixture of T-TBS with 0.1% Tween in 2% milk and the
respective antibodies caspase-3 (Santa Cruz biotechnology, Santa Cruz, CA), cytochrome
c , GAPDH (Cell Signaling Technology, Inc, Danvers, MA) and manganese superoxide
dismutase (MnSOD; Cayman Chemicals, Ann Arbor, MI) in 1:1000 dilution.
Subsequently, the membrane was incubated in the respective secondary antibody
(1:10,000) for 1 hr at room temperature. Final visualization was carried out with the
enhanced chemiluminescence kit (Bio-Rad, Hercules, CA). The protein bands were
quantified by densitometry (Haorah et al., 2005).
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3.1.12. Apoptosis Measurement. Apoptosis was quantified using the ethidium
bromide and Acridine Orange assay (Duke and cohen, 1999). Briefly, control and treated
cells (106) were transferred to microcentrifuge tubes and pelleted for 10 min at 1,000 xg.
After centrifugation, the cell-rich pellets were resuspended in a mixture containing 2 µl
of ethidium bromide (100 µg/ml) and 2 µl of Acridine Orange (100 µg/ml). The stained
cells were observed with an Olympus IX51 inverted microscope at 600× total
magnification with a UPLFLN 60 X NA 1.25 objective. FITC (EX 482/35 506DM
EM536/40) and TexasRed (EX 562/40 593DM EM 692/40) filters were used
(Brightline). Images were captured with a Hamamatsu ORCA285 CCD camera. The
shutters, filters and camera were controlled using SlideBook software (Intelligent
Imaging Innovations, Denver, CO). Live, apoptotic, and necrotic cells were differentiated
from each other using fluorescence microscopy on the basis of definitive nuclear and
cytosolic fluorescence and distinct morphological changes, including membrane
blebbing, nuclear and cytosolic condensation, and nuclear fragmentation.
3.1.13. Measurement of Intracellular Calcium Concentration ([Ca2+]in).
hCMEC/D3 cells were briefly plated on glass-bottom dishes and allowed to attach for 24
hr. The cells were exposed to different concentrations of AZT + IDV combination for 72
hr. The cells were washed with PBS and were incubated for 20 min to allow efficient
loading of membrane permeable Fura-2 AM in a serum-free media. The entire medium
was then removed and the cells were washed with PBS twice to eliminate
extracellular Fura-2AM. Following this wash, serum-free medium was added to the cells,
which were then allowed to reach homeostasis by incubation for the remaining 20 min at
37 0C. The cells were then placed on the stage of an inverted fluorescence microscope
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(InCyt Basic IM Fluorescence Imaging System, Intracellular Imaging Inc.). The cells
were excited at 340 nm and 380 nm while emission was monitored at 510 nm at an
acquisition rate of 10 Hz. The ratio of fluorescence measured after excitation at the two
wavelengths (F340/F380) was proportional to the free calcium concentration. In each
independent experiment, 25 cells were selected to measure the [Ca2+]in and averaged
(Huang et al., 2010).
3.1.14. Trans-Endothelial Electric Resistance (TEER) Measurement.
Transendothelial electric resistance (TEER) measurement by an EVOM voltohmmeter
(World Precision Instrument, Sarasota, FL, USA) assessed the tightness of the
hCMEC/D3 monolayer. hCMEC/D3 cells were seeded onto collagen-coated inserts with
a pore size of 0.4 μm at densities of 15×103/well, and allowed to culture until a
monolayer formed (4–7 days). The cell monolayer was then treated with AZT + IDV or a
serum-free media for 72 hr. After this, the media was replaced with 150 μl of fresh
medium. The insert containing the cell monolayer was then transferred in to a fresh plate
containing 500 μl of serum-free medium. The TEER reading was recorded immediately.
TEER values were calculated as: Resistance×0.33 Ωcm2 (insert surface area) and were
expressed as a percentage of control. Thus, resistance is inversely proportional to the
effective membrane (Zhang et al., 2009).
3.1.15. Dextran Permeability Study. hCMEC/D3 cells were seeded onto
collagen-coated inserts with a pore size of 0.4 μm at densities of 15 × 103/well, and
allowed to culture until a monolayer formed. The cell monolayer was then treated with
AZT or serum-free media for 72 hr. After this, the medium in the insert was replaced
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with 150 μl of FITC labeled dextran, and was transferred to a fresh plate well, containing
500 μl of serum-free medium. The plates were incubated for 30 min at room temperature,
and 100 μl of the plate’s well solution were removed and transferred to a 96-well plate.
Fluorescence was read with a 485 nm excitation and 530 nm emission, using a microplate
reader (Fluostar, BMG Labtechnologies, Durham, NC, USA) (Zhang et al., 2009).
3.1.16. Determination of Protein. Protein levels of the cell samples were
measured by the Bradford method (Bradford, 1976). Concentrated Coomassie Blue (BioRad, Hercules, CA) was diluted 1:5 (v/v) with distilled water. 20 μl of the diluted cell
homogenate were then added to 1.5 ml of this diluted dye, and absorbance was measured
at 595 nm using a UV spectrophotometer (Shimadzu Scientific Instruments, Columbia,
MD). Bovine serum albumin (BSA) was used as the protein standard.
3.1.17. Statistical Analysis. Group comparisons were performed using the oneway analysis of variance (ANOVA) test and the TUKEYS post hoc test. Statistical
analyses were made using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA).
Statistical significance was set at p < 0.05.
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4. IN VITRO RESULTS
4.1. VIABILITY AND OXIDATIVE STRESS STUDIES
4.1.1. Antiretroviral Drugs Decrease Viability. To determine whether the
HAART drug combination affects the viability of endothelial cells, we treated
hCMEC/D3 cells with AZT + IDV. Effects of AZT + IDV on cell viability of
hCMEC/D3 were determined by using the calcein AM assay. Cells were treated with
drug combinations ranging from 5 µM to 200 µM each, used in previously reported
studies with immortalized endothelial cells (Collier et al., 2003). Treatment with drugs
for 24 hr did not show a significant trend by ANOVA, except for the 50 µM, 100 µM,
and 200 µM treated groups (p<0.05). However, analysis of individual differences with
Tukey’s post test showed that only the highest concentration (200µM) was different from
that of the 50µM and 100 µM treated groups (p<0.05), and produced a moderate decrease
in cell viability (~ 21% decrease) (Figure 4.1). Treatment with AZT + IDV induced a
more prominent decrease in viability after 72 hr (Figure 4.2), in a dose-dependent
manner. 50 µM, 100 µM, and 200 µM concentrations of AZT + IDV caused an increase
in cell death (approximately 21%, 43%, and 65%, respectively, at p<0.05), and, hence,
these concentrations of AZT + IDV were used for further studies.
The cytotoxic effect of AZT+ IDV treatment assessed using light microscopy
shows the deleterious effects on viability. Figure 4.3 shows the effect of AZT+IDV on
morphology of hCMEC/d3 cells. Control cells appear to be well-differentiated whereas
treated group with AZT+IDV shows round and floating cells indicating cells undergoing
death. Cells treated with 100 µM of AZT or IDV alone showed that AZT was more toxic
than IDV in these cells (p<0.05). IDV and AZT alone treated cells showed a decrease in
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viability of 23% and 34%, respectively, whereas cells treated with an AZT + IDV
combination showed only a 43% decrease in viability (Figure 4.4).
4.1.2. Effect of HAART Drugs on ROS Production. To examine the role of
oxidative stress in endothelial cell death, we measured the levels of ROS in endothelial
cells treated with drugs using the DCFH2-DA fluorescent assay. ROS are a highly
transient species and in order to measure them, an intermediate time point of 48 hr was
selected. Endothelial cells were incubated with AZT + IDV for 48 hr followed by
washing to remove the drugs. Re-incubation of hCMEC/D3 cells in the presence of the
dye DCF for 0.5 hr resulted in an increase in fluorescence compared to control.
Treatment with AZT + IDV induced a 1.5 to 2 fold increase in ROS production after the
48-hr treatment (Figure 4.5). Although the ROS levels were different than those of the
control (p<0.05), no significant difference was observed between those of treated groups.
4.1.3. Effect of HAART Drugs on GSH levels. Oxidative stress or a high level
of ROS generation leads to the decline in cellular antioxidants like GSH. The levels of
GSH were measured after treatment with AZT+IDV to further assess the role of oxidative
stress in cytotoxicity. The levels of glutathione in all treated groups were significantly
lower than that of the control (Figure 4.6). In the AZT + IDV treated groups, dosedependent decreases in the GSH levels were observed. Cells treated with 200 µM
AZT+IDV had a 65% decrease in GSH levels, as compared to controls, whereas those
treated with 100 µM and 50 µM doses experienced decreases of 50 % and 40% with
respect to that of the control (p<0.05).
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4.1.4. HAART Effects on Lipid Peroxidation Levels. An increase in ROS and
a decrease in GSH led to high levels of reactions between free radicals and membrane
lipids, causing lipid peroxidation in the cells. This was estimated by measuring the levels
of malondialdehyde (MDA), a stable by-product of lipid peroxidation. MDA levels were
significantly increased in all treated groups, as compared to control. MDA levels in the
group treated with 50 µM (Figure 4.7) were arithmetically higher, but this did not reach
statistical significance. A 1.5- to 3-fold increases in MDA levels were observed in the
cells treated with 100 µM and 200 µM doses of AZT+IDV, as compared to the controls
(p <0.05).
4.1.5. Antioxidant Enzyme Activity. Catalase is a common enzyme found in
nearly all living organisms that are exposed to oxygen, where it functions to catalyze the
decomposition of hydrogen peroxide to water and oxygen. Activity of catalase in AZT+
IDV treated hCMEC/D3 cells is shown in figure 4.8. Catalase activity decreased
significantly in cells treated with AZT+IDV treated groups (p<0.05). A dose dependent
decrease in catalase activity was observed indicating that AZT+IDV treatment modified
the ability of the cells to cleave hydrogen peroxide and protect cells.
4.2. HAART DRUGS DISRUPT MITOCHONDRIAL FUNCTION
4.2.1. Dissipation of Mitochondrial Membrane Potential (ΔΨm). One
important intracellular target of drugs is mitochondria, which is also a source of ROS
inside cells. Any disruption in mitochondrial permeability and function can be assessed
by measuring the changes in mitochondrial membrane potential (ΔΨm). The decrease in
ΔΨm was demonstrated by using membrane permeable potentiometric dye, JC-1. Cells

35

with mitochondrial dysfunction showed primarily green fluorescence, whereas healthy
cells were differentiated with red and green fluorescence. As shown in Figure 4.9, control
cells stained both red and green, whereas a dose-dependent decrease in red fluorescence
was seen in treated groups. Although the 200 µM treated group showed specks of red
fluorescence, these images did not merge into the cytoplasmic area of cells (green
fluorescence), as seen in previous groups, and appeared to be floating dye aggregates.
Decreases in the red fluorescence across treated groups indicated that AZT + IDV
treatment dissipated ΔΨm in the BBB cells. These results support our hypothesis that
AZT + IDV treatment depolarizes the mitochondria membrane potential, disrupting the
mitochondrial function, and resulting in cell death.
4.2.2. Changes in ATP levels. ATP levels were measured as another test for
mitochondrial function. Treatment with AZT + IDV after 72 hr resulted in a dosedependent decrease in ATP levels (Figure 4.10). Compared to control, the ATP levels
decreased 20-50 % in treated groups (p<0.05). These results also add to the evidence that
HAART drugs affect mitochondrial function.
4.2.3. Effect of AZT+IDV on MnSOD Protein Expression. hCMEC/D3 cells
were maintained in supplemented EGM-2 (see Methods). Cells were incubated with 50
µM, 100 µM, and 200 µM of AZT + IDV for 72 hr. MnSOD protein expression was
monitored by western blot analysis. The levels of protein expression of MnSOD appeared
to be slightly elevated in the 50 µM treated group, whereas no change was detected in the
100 µM sample. There was, however there was a significant decrease in the expression of
MnSOD protein in the 200 µM treated group (Figure 4.11).
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4.3. EFFECT OF HAART DRUGS ON APOPTOTIC CELL DEATH
4.3.1. Effect of HAART on Cytochrome c and Procaspase-3 Expression. The
disruption of mitochondrial membrane function is known to result in the release of the
mitochondrial enzyme cytochrome c into the cytosol. The levels of cytochrome c release
were measured to determine if changes in mitochondrial membrane potential correlate
with the initiation of apoptosis (Skulachev, 1998). Figure 4.12 shows levels of
cytochrome c released from mitochondria into the cytoplasm. There was an increase
(~1.5 -2.0 fold) in cytochrome c released in 50 µM and 100 µM (p<0.05). Cytochrome c
levels in 200 µM treated group were arithmetically higher, but were not significant when
compared to that of the control. As additional evidence of apoptosis occurring in
endothelial cells treated with AZT + IDV, we measured the levels of procaspase-3
protein, as shown in Figure 4.13. Although there was an increase in the expression of
procaspase-3 in all treatments, there was an even higher increase in the 50 µM - treated
cells, as compared to other treated groups.
4.3.2. Apoptosis Detection Using Acridine Orange and Ethidium Bromide.
To corroborate that apoptosis had been induced by AZT+IDV, hCMEC/D3 cells were
analyzed in the presence of acridine orange and ethidium bromide staining (AO/EB
staining). Acridine orange is a vital dye that will stain both live and dead cells, whereas
ethidium bromide will stain only those cells that have lost their membrane integrity
(Kasibhatla et al., 2006). As a control, cells were cultured in a complete media and
stained with AO/EB (Figure 4.14A). Cells stained green represented viable cells, whereas
yellow staining represented early apoptotic cells, and reddish or orange staining indicated
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late apoptotic cells. As shown in Figure 4.14B, 50 µM treated hCMEC/D3 cells showed
changes in cellular morphology, including chromatin condensation, membrane blebbing,
and fragmented nuclei. Figs. 4.14C and 4.14D showed similar features for 50 µM
treated cells (Figure 4.14B), but had extra features of late stage apoptotic bodies when
hCMEC/D3 cells were treated with 100 µM and 200 µM of the AZT + IDV treated
group.
4.4. INTRACELLULAR CALCIUM [CA2+]in MEDIATES APOPTOSIS
It is now known that intrinsic pathways in apoptosis involve the exchange of
Ca2+ signals between the ER and the mitochondria that coordinate the precommitment
phase of apoptosis (Pinto et al., 2008). It has also been shown that oxidative stress
increases the intracellular calcium concentration leading to activation of endonucleases,
which degrade DNA and, ultimately, contribute to cell death (Annuziato et al., 2003) In
order to explore the role of calcium in apoptosis by AZT + IDV, we assessed the levels of
[Ca2+]in using fluorescent microscopy. We detected a 1.5-2.5 fold increase (p<0.05) in
calcium levels in the 100 µM and 200 µM treated groups, when compared to levels in the
control (Figure 4.15). Although the 50 µM treated group showed an increase in
[Ca2+]in levels, these were not statistically different than those of the control, but 100 µM
and 200 µM treated groups were different from 50 µM treated group (p<0.05). These
results imply that [Ca2+]in mediates the mitochondrial permeability transition, thereby
releasing intra-mitochondrial contents like cytochrome c during apoptosis.
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4.5. EFFECT OF HAART DRUGS ON THE BBB INTEGRITY
Regulation of the flow of substances through intercellular spaces depends on the
integrity of the BBB. Permeability studies, such as dextran cell permeability assay and
TEER assays were used in this study to assess the integrity of a monolayer of endothelial
cells as they simulate the integrity of the BBB (Gandhi et al., 2010). The resistance
measured across the monolayer of cells showed a decrease in resistance of approximately
10-30% across the treated groups (Figure 4.16A). To further support these findings, we
also measured the amount of FITC labeled dextran that leaked across the monolayer
using fluorometry after treatment. In agreement with the data for TEER, there was a 1060% increase in the permeability of the layer, as seen by the increase in fluorescence
across the treated groups. In both of these studies, the 100 µM and 200 µM treated groups
were different from the control (p<0.05). Although the 50 µM treated group was not
significant when compared to control, they were arithmetically higher than control.
Tukey post hoc analysis showed that the 100 µM and 200 µM treated groups was
different from the 50 µM treated group (p<0.05).This indicated that intercellular
junctions between the endothelial cells were compromised with HAART treatment
(Figure 4.16B).
4.6. EFFECT OF NACA ON AZT+IDV INDUCED TOXICITY
4.6.1. Cytotoxicity Studies. Figure 4.17 displays the results of cytotoxicity
studies of NACA in hCMEC/D3 cells. Cells were incubated with 0.25, 0.5, 0.75, 1, 2, 5,
10 mM NACA for 24 h, after which calcein AM was added and fluorescence levels were
measured. Reagent controls and cell controls were included. These results indicated that
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except the 10 mM NACA treated group all the other groups had cell viability comparable
to that of the control. The highest concentration of 10 mM NACA appeared to be mild
cytotoxic to cells, so a minimal dose of 2 mM NACA, the dose without any cytotoxic
effects was selected for our studies.
The protective effect of NACA in AZT+IDV induced cell death in hCMEC/D3
cells is shown in Figure 4.18. Although the cells appeared to be rescued from the
cytotoxic effect of AZT+IDV drugs, the increase in cell viability appear to be arithmetic,
rather than significant, when compared to the treated group. The viability in the
AZT+IDV treated group decreased to approximately 65%, when compared to control.
Pretreatment with NACA could only raise the viability to 77% when compared to control.
4.6.2. Reactive Oxygen Species (ROS) Levels. Our studies with AZT+IDV
showed a dose dependent increase in ROS levels in endothelial cells. In order to test the
effect of NACA on ROS production in AZT+IDV treated groups, cells were
preincubated with 2 mM NACA for 1 hr. Figure 4.19 shows the scavenging effect of
NACA on free radicals in treated cells. NACA pretreated hCMEC/D3 cells had
significantly lower levels of ROS when compared to that of the treated group (p<0.05)
and it appeared to be almost equal to that of the control. These results suggest that the
protective effect of NACA may partly be from the ability to scavenge free radicals in
oxidative stress.
4.6.3. NACA Effect on Glutathione (GSH) Levels. Depletion of cellular
antioxidants like GSH is commonly observed in oxidatively challenged conditions. Thiol
antioxidants are known to replenish cells with GSH levels in these situations, so we
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tested the ability of NACA to increase GSH levels in AZT+IDV treated. Figure 4.20
shows the effect of NACA on GSH levels in drug treated groups. GSH levels in
endothelial cells in the NACA pretreated group had significantly high levels of GSH
(approximately ~70% of the control) when compared to that of the AZT+IDV treated
groups (p<0.05). These results suggest that NACA can prevent oxidative stress in cells by
being uses as substitute to GSH for scavenging free radicals or indirectly by increasing
the GSH levels.
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Figure 4.1. Effect of AZT + IDV treatment for 24 hr on viability. Effect of AZT +
IDV treatment for 24 hr (5 µM-200 µM) on hCMEC/D3 cell viability as indicated by
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical
differences (p<0.05) as compared to untreated control. # Statistical difference (p<0.05)
compared to 50 µM and 100 µM group.
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Figure 4.2. Effect of AZT + IDV treatment for 72 hr on viability. Effect of AZT +
IDV treatment for 72 hr (5 µM-200 µM) on hCMEC/D3 cell viability, as indicated by
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical
differences (p<0.05) as compared to untreated control.
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(A) Control

(B) AZT+IDV (200 µM)

Figure 4.3. Morphological assessment of AZT +IDV treatment. hCMEC/D3 cells were
treated with or without AZT+IDV (200 µM) for 72 hr. The morphology was assessed
using an Olympus inverted microscope. Arrow indicates dead cells in 200 µM group.
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Figure 4.4. Effect of AZT or IDV alone on viability. Effect of AZT or IDV alone and in
combination treatment (100 µM) for 72hr on hCMEC/D3 cell viability as indicated by
uptake of calcein. Results as mean percent of controls (Mean±SEM; n=5). * Statistical
differences (p<0.05) as compared to untreated control. *** Statistical difference (p<0.05)
compared to AZT treated group.
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Figure 4.5. Reactive oxygen species (ROS) production. Reactive oxygen species (ROS)
production induced in hCMEC/D3 cells treated with 50 µM, 100 µM and 200 µM, AZT
+IDV for 48 hr. Cellular ROS levels were assessed using DCFH2-DA. Results expressed
as mean values (Mean±SEM; n=5). * Statistical differences (p<0.05) as compared to
untreated control.
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Figure 4.6. Glutathione (GSH). AZT + IDV (50 µM, 100 µM, and 200 µM) exposure led
to intracellular glutathione (GSH) decrease in a dose-dependent manner. hCMEC/D3
cells were treated for 72 hr and GSH levels were measured using HPLC method
described in Materials and Methods section. Results expressed as mean percent of
controls (Mean±SEM; n=4). * Statistical differences (p<0.05) as compared to untreated
control.
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Figure 4.7. Lipid peroxidation levels. Lipid peroxidation in hCMEC/D3 cells. AZT +
IDV (50 µM, 100 µM, 200 µM) treatment for 72 hr caused oxidative stress resulting in an
increase in malondialdehyde (MDA) levels, a lipid peroxidation metabolite. MDA levels
were measured using HPLC method described in the Materials and Methods section.
Results expressed as mean percent of controls (Mean±SEM; n=4). ). * Statistical
differences (p<0.05) as compared to untreated control.
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Figure 4.8. Effect of AZT+ IDV on antioxidant enzyme catalase activity. Cells were
treated for 72 hr with the drug combination and activity was estimated using spectro
photometric method. Each value is an average of at least triplicate values with standard
error mean bars (n=4). * Statistical differences (p<0.05) as compared to untreated control.
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Figure 4.9. Analysis of mitochondrial membrane potential. ΔΨm was analyzed in
adherent hCMEC/D3 after 72 hr of AZT+IDV treatment, using the potential-dependent
aggregate-forming lipophilic cation JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'tetraethylbenzimidazole carbocyanide iodide). Left image represents JC-1 dye
aggregation in mitochondria with intact membrane potential. Mitochondria exhibit red
fluorescence if ΔΨm is preserved. Middle image represents JC-1 monomers exhibiting
green fluorescence in cytoplasm of cells. Mitochondria in treated cells showed a dosedependent decrease in red fluorescence due to loss of ΔΨm. Merged images are
represented on extreme right. Each experiment was performed in triplicate (n = 3) and
generated similar changes in fluorescence.
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Figure 4.10. ATP levels. ATP levels were measured with the bioluminescence assay
(Promega) in AZT + IDV (50 µM, 100 µM, 200 µM) treated cells for 72 hr. Exposure to
drugs showed a dose-dependent decrease in ATP levels. * Statistical differences (p<0.05)
as compared to untreated control (Mean±SEM; n=4).
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Figure 4.11. Expression of manganese superoxide dismutase protein. (MnSOD)The
expression of manganese superoxide dismuatase in hCMEC/D3 cells treated with AZT +
IDV for 72 hr Equal amounts of cellular protein were separated on 12% SDS-PAGE gels
and transferred to nitrocellulose membranes as described in Materials and Methods.
GAPDH was used as an internal control.

52

Figure 4.12. The expression of apoptosis-related protein cytochrome c. hCMEC/D3
cells treated with AZT + IDV for 72 hr. Equal amounts of cellular protein were
fractionated on 12% SDS-PAGE gels and transferred to nitrocellulose membranes as
described in Materials and Methods. GAPDH was used as an internal control.
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Figure 4.13. The expression of apoptosis-related protein procaspase-3. hCMEC/D3cells
treated with AZT + IDV for 72 hr. Equal amounts of cellular protein were separated on
12% SDS-PAGE gels and transferred to nitrocellulose membranes as described in
Materials and Methods. GAPDH was used as an internal control.
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Figure 4.14. Apoptosis detection using acridine orange with ethidium staining.
hCMEC/D3 cells were treated with AZT + IDV for 72 hr and were stained with AO/EB
mixture. (A) Control and viable cells appearing only green due to acridine orange
staining. (B) 50 µM treated hCMEC/D3 cells showing changes in cellular morphology
for early apoptosis and appearing orange with ethidium staining. Dashed arrow indicates
cells with chromatin condensation; rounded dotted arrow indicates cells with fragmented
nuclei; dashed dotted arrow indicates cells with membrane blebbing. (C) 100 µM treated
group showing morphological similar to 50 µM treated group with some late apoptotic
features. Full white arrow indicates the presence of apoptotic bodies. (D) 200 µM treated
group with cells showing chromatin condensation and late apoptotic features like
apoptotic bodies. Necrotic cells appearing red with ethidium staining. Each experiment
was performed in triplicate (n = 3) and generated similar morphological features.

55

Figure 4.15. Effect of AZT + IDV treatment on intracellular calcium levels [Ca2+]in
hCMEC/D3 cells were treated with AZT + IDV for 72 hr and calcium levels were
measured as described in Material and Methods section. Results expressed as mean
percent of controls (Mean±SEM; n=3). Each value is average of atleast triplicate values
with standard error mean bars. * Statistical differences (p<0.05) as compared to untreated
control. *** Statistical difference (p<0.05) compared to 50 µM treated group.
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Figure 4.16. Effect of AZT + IDV on TEER and dextran permeability. (A) AZT + IDV
treatment significantly reduced TEER, and TEER measurement across the hCMEC/D3
monlayer measured the BBB integrity and tightness. TEER values recorded in ohms
(Ω)/insert area were corrected to Ω/cm2 from three experiments in triplicate. Results as
mean percent of control (Mean±SEM; n=3). (B) Monolayer treatment for 72 hr with
AZT + IDV increased the permeability of FITC-labeled dextran across the BBB.
Fluorescence measured was then expressed as mean percent of control (Mean±SEM;
n=3). * Statistical differences (p<0.05) as compared to untreated control. *** Statistical
difference (p<0.05) compared to 50 µM treated group.
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Figure 4.17. Effect of NACA on hCMEC/D3 cell viability. Cells were treated with
different concentrations of NACA in serum free media and viability was assessed using
calcein assay. Each value is an average of at least triplicate values with standard error
mean bars (Mean±SEM; n=5).
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Figure 4.18. Effect of NACA on AZT+IDV induced cell death. Cells were pretreated
with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100 µM) for 72 hr. Viability
was assessed using calcein AM fluorescent assay. Each value is the average of at least
triplicate values with standard error mean bars (Mean±SEM; n=5).
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Figure 4.19. Effect of NACA on AZT+IDV induced ROS production. Cells were
pretreated with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100 µM) for 72 hr.
Results are expressed as mean percent controls (Mean± SEM; n=4). * Statistical
differences (p<0.05) as compared to untreated control. # Statistical differences (p<0.05)
as compared to AZT + IDV treated control.
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Figure 4.20. Effect of NACA on GSH levels in AZT+IDV treated cells. hCMEC/D3
cells were pretreated with 2 mM NACA for 1 hr and then exposed to AZT+IDV (100
µM) for 72 hr. Results are expressed as mean percent controls (Mean± SEM; n=4). *
Statistical differences (p<0.05) as compared to untreated control. # Statistical difference
(p<0.05) compared to AZT+IDV treated group.
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5. INVIVO EXPERIMENTS
5.1 MATERIALS AND METHODS

5.1.1 Materials. F344 rats (normal and HIV-1 transgenic) were obtained from
Harlan Laboratories (Indianapolis, IN). N-acetylcysteine amide was provided by Dr.
Glenn Goldstein (David Pharmaceuticals, NewYork, NY, USA). N-(1-pyrenyl)maleimide (NPM) was purchased from Sigma (St. Louis, MO). High-performance liquid
chromatography (HPLC) grade solvents were purchased from Fisher Scientific (Fair
Lawn, NJ). Antiretroviral drugs (ART), AZT and IDV were a gift from the National
Institutes of Health AIDS Research and Reference Reagent Program. All other chemicals
were purchased from Sigma (St. Louis, MO), unless stated otherwise.
5.1.2. Animal Experiments. Male F344 normal and HIV-1 transgenic (Tg) rats
(200-250 g, 3 months old) were housed in a controlled temperature (20–23 0C) and
controlled-humidity (~55%), in an animal facility, with a 12 h light and dark cycle. The
animals had unlimited access to rodent chow and water, and were utilized after 1week of
acclimatization. All animal procedures were conducted under an animal protocol
approved by the Institutional Animal Care and Use Committee of the Missouri University
of Science and Technology. The normal rats were divided into control and NACA
control. HIV Tg rats were classified as experimental group. The HIV Tg rats in the
experimental group further were divided into four major groups (n = 4 each): HIV group,
HIV+ART, HIV+ NACA and HIV+ ART +NACA. All animals in the control and
experimental groups were injected intraperitoneally (i.p) with either saline or NACA (500
mg/kg body weight), 30 min before exposure to ART drugs. The animals in the
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respective experimental group were injected i.p with ART drugs (AZT+IDV, each
15mg/kg body weight for 10 days (Jiang et al., 2009). The rats were sacrificed 24 h after
the last exposure by urethane injection. All rats were weighed at the beginning and at the
end of the study. Following sacrifice, the brains were harvested and divided into two
parts, and the first half were placed in a cold stock buffer (25 mM HEPES, 1% dextran in
minimum essential medium) (Gibco BRL, Grand Island, N.Y.), at pH 7.4 on ice and the
remaining tissue was stored in an antioxidant buffer [8.6mM sodium phosphate dibasic
(Na2HPO4), 26.6 mM sodium phosphate monobasic (NaH2PO4), 50 µM
butylhydroxytoluene (BHT), 10mM aminotriazole, 0.1mM diethyltriaminepentaacetic
acid (DTPA)] at −80 0C for further analysis.
5.1.3 Isolation of Brain Microvessels. Microvascular endothelial cells were
isolated using an established protocol (Wu et al., 2003). Briefly, brain tissues from rats
were homogenized in cold stock buffer (25 mM HEPES, 1% dextran in minimum
essential medium) (Gibco BRL, Grand Island, N.Y.), at pH 7.4 on ice. The homogenates
were then filtered through a series of nylon mesh membranes, after which they were
mixed with an equal volume of 40% dextran in stock buffer, and centrifuged at 5,000 × g
for 15 min at 4°C. The pellet obtained is re-suspended in a stock buffer and filtered
through a 25-µm pore-size nylon mesh membrane (Bio-Design, Carmel, NY). The microvessels were then washed from the surface of the membrane with the stock buffer,
collected, and centrifuged at 5,000 × g for 15 min at 4°C, after which they were resuspended in an incubation buffer [129 mM NaCl, 2.5 mM KCl, 7.4 mM Na2HPO4,
1.3 mM KH2PO4, 0.63 mM CaCl2, 0.74 mM MgSO4, 5.3 mM glucose, 0.1 mM ascorbic
acid (pH 7.4)], with a small aliquot being reserved for verification of an enriched micro-
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vessel preparation by light microscopy. About 97.5% of the cells isolated were capillary
endothelial cells, 1.6% were fibroblast-like cells, and 0.9% were erythrocytes. There were
no glias, neurons, synaptosomes, or synaptic complexes, although there were some other
membrane profiles and myelin fragments.
5.1.4. Determination of Glutathione (GSH) Levels. The levels of GSH in the
BBB microvessels and brain were determined by RP-HPLC, according to the method
developed in our laboratory (Winters et al., 1995). The HPLC system (Thermo Electron
Corporation) consisted of a Finnigan Spectra System vacuum membrane degasser (model
SCM1000), a gradient pump (model P2000), autosampler (model AS3000), and a
fluorescence detector (model FL3000) with λex=330 nm and λem=376 nm. The HPLC
column used was a Reliasil ODS-1 C18 column (5-µm packing material) with 250×4.6
mm i.d (Column Engineering, Ontario, CA). The mobile phase (70% acetonitrile and
30% water) was adjusted to a pH of 2 with acetic acid and o-phosphoric acid. The NPM
derivatives of GSH were eluted from the column isocratically at a flow rate of 1 ml/min.
The microvessel pellets or brain tissues obtained were homogenized in 1 ml of serine
borate buffer (SBB,100 mM Tris buffer containing 10 mM borate and 5 mM serine with
1 mM diethylene triaminepentacetic acid; Ph=7.4), centrifuged, and 250 µl of the
supernatants were added to 750 µl of 1 mM NPM. The resulting solution was incubated
at room temperature for 5 min, and the reaction was stopped by adding 10 µl of 2N HCl.
The samples were then filtered through a 0.45 µm filter and injected into the HPLC
system.

64

5.1.5. Determination of Malondialdehyde (MDA). The MDA levels were
determined according to the method described elsewhere (Draper et al). Briefly, 550 μl of
5% trichloroacetic acid (TCA) and 100 μl of 500 ppm butylated hydroxytoluene (BHT) in
methanol was added to 350 μl of the BBB microvessel or brain homogenates, and boiled
for 30 min in a water bath. After cooling on ice, the mixtures were centrifuged, and the
supernatant was collected and mixed 1:1 with saturated thiobarbituric acid (TBA). The
mixture was again heated in a water bath for 30 min, followed by cooling on ice. 500 μl
of the mixture was extracted with 1 ml of n-butanol and centrifuged to facilitate the
separation of phases. The resulting organic layers first filtered through 0.45 μm filters
and then injected into the HPLC system (Shimadzu, US), which consisted of a pump
(model LC-6A), a Rheodyne injection valve and a fluorescence detector (model RF 535).
The column was a 100 × 4.6 mm i.d C18 column (3 µm packing material, Astec,
Bellefonte, PA). The mobile phase used contained 69.4% sodium phosphate buffer, 30%
acetonitrile, and 0.6% tetrahydrofuran. The fluorescent product was monitored at λex=
515 nm and λem= 550 nm. Malondialdehyde bis (dimethyl acetal), which gives
malondialdehyde on acid treatment, was used as a standard.
5.1.6. Measurement of Superoxide Levels. BBB microvessels were suspended
in PBS, pH 7.2, containing 100 μg/ml bovine serum albumin and protease inhibitor
cocktail (EDTA free complete protease mix; Roche Diagnostics, Indianapolis, IN).
Reduced streptolysin O (5 units/ml; Sigma Aldrich) was added, and the mixture was
incubated for 10 min at 37 °C (O’brien et al., 2009). The permeabilized cells were chilled
to 4 °C, harvested by centrifugation, and washed with phosphate buffer, pH 7.2. To
measure superoxide production, brain microvessels were resuspended in duplicate tubes,
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with and without 200 units of SOD, containing 30 mM of 3-(N-morpholino)
propanesulfonic acid (MOPS (pH 7.2), 100 μM flavin adenine dinucleotide (FAD), and
100 μM oxidized cytochrome c, incubated at room temperature for 5 min, and
nicotinamide adenine dinucleotide phosphate (NADPH) added to a final concentration of
200 μM. The change in optical density at 550 nm was recorded every 5 min for 1 hr. At
the conclusion of the experiment, cells were lysed in 20 mM HEPES buffer containing
1% Triton X-100, and the protein was quantitated using the biorad protein assay.
Superoxide production was expressed as SOD-inhibitable cytochrome c
reduction/min/mg protein.
5.1.7. Measurement of NADPH Oxidase Activity. NADPH oxidase activity was
measured in brain using the lucigenin assay. Briefly, frozen brain samples were
homogenized in protease inhibitor-containing buffer at 4°C, and then subjected to
differential centrifugation to isolate purified cell membranes (obtained after sequential
centrifugations of 1300 x g to remove nuclei, 13,000 x g to remove mitochondria).
Membrane samples were then incubated with 5 µM lucigenin and 100 µM NADPH, and
NADPH oxidase activity was measured immediately using a luminescence plate reader at
37°C. To eliminate the background level of luminescence, membrane fractions of the
samples were also incubated in the presence of 1 µM diphenyl iodonium chloride (DPI),
a broad-spectrum flavin oxidase inhibitor.
5.1.8. Measurement of Nitrite Levels in the Brain. Nitrite levels in the BBB
microvessels were determined using a commercially available kit from Cayman Chemical
Company (Ann Arbor, MI). Briefly, this assay measures the nitrite concentration in two-
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steps. The first step involves the conversion of nitrate to nitrite using nitrate reductase,
and the second step converts the nitrite into a deep purple azo compound using the greiss
reagent. Photometric determination of the absorption at 540 nm accurately determines the
NO2- concentration.
5.1.9. Determination of Protein. Protein levels of the cell samples were
measured by the Bradford method. Concentrated Coomassie Blue (Bio-Rad, Hercules,
CA) was diluted 1:5 (v/v) with distilled water. 20 μl of the diluted cell homogenate was
added to 1.5 ml of this diluted dye, and absorbance was measured at 595 nm using a UV
spectrophotometer (Shimadzu Scientific Instruments, Columbia, MD). Bovine serum
albumin (BSA) was used as the protein standard.
5.1.10. Statistical Analysis. Group comparisons were performed using the oneway analysis of variance (ANOVA) test and the TUKEYS post hoc test. Statistical
analyses were made using GraphPad Prism 5.01 (GraphPad Software Inc., La Jolla, CA).
Statistical significance was set at p < 0.05.
5.2. IN VIVO RESULTS
5.2.1. Changes in Glutathione Levels of Brain Microvessels and Brain. Table
5.1 shows the effect of viral proteins and ART drugs on GSH levels in blood-brain
barrier. Compared to the controls, the HIV treated animals had a decrease (~ 3 fold) in
the GSH levels in their blood brain barrier. A significant and drastic decrease (~ 6 fold)
in the levels of GSH was observed in HIV transgenic animals treated with ART drugs
when compared to controls. In this study, animals treated with ART also experienced a ~
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1.5 fold decrease in GSH levels, as compared to the HIV group. Animals pretreated with
NACA in both the HIV and HIV +ART groups showed an increase in GSH levels.
Evaluation of GSH levels in the brains of HIV transgenic animals and ART
treated group are shown in Table 5.1. Compared to control, the HIV transgenic animals
had a significantly lower level of GSH. Similarly, the HIV+ART group also had
decreased levels of GSH in relation to control. There was no significant difference
observed between the HIV and ART treated HIV group. Treatment with NACA elevated
the GSH to a level similar to that of control group in both the HIV and ART treated
group. These results suggest that viral proteins induce oxidative stress by decreasing the
levels of GSH and these effects appear to be more potentiated with concomitant use of
ART drugs. These outcomes also indicate the potent antioxidant ability of NACA to
reverse these effects and replenish GSH in oxidatively challenged cells.
5.2.2. Effect of HIV Proteins and ART on MDA Levels in Brain. A significant
increase in the level of MDA was observed in the brain tissue of HIV transgenic animals,
as compared to those of the control and the NACA-alone treated group. HIV Tg animals
treated with ART had a higher MDA levels than those of the control, but were similar to
those of HIV group (Table 5.2). However, animals in the HIV group, pre-treated with
NACA, had significantly lower MDA level than those of the untreated group, indicating
that NACA was protecting the animals from oxidative stress-induced damage. Also
animals in the HIV+ART group had lower levels of MDA than those of the control
group, but similar to those of NACA group.
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5.2.3. NADPH Oxidase Activity. The NADPH oxidase, a membranebound enzyme complex, normally generates superoxide by electrons by transferring
electrons from NADPH inside the cell across the membrane and coupling these to
molecular oxygen to produce the superoxide radical (O2*-). Figure 5.1 shows that,
compared to the controls, HIV and HIV+ART treated animals experienced a significant
increase in the NADPH oxidase activity in the brain. Pretreatment of the HIV+ART
treated animals with NACA significantly decreased the NADPH oxidase activity,
indicating that NADPH oxidase activation might be one of the reasons for increased
oxidative stress in these animals.
5.2.4. Effect of ART Drugs on Superoxide levels in BBB. Several studies have
shown that NADPH oxidase is the most important source of superoxide anion in
phagocytic and vascular cells. Increase in NADPH oxidase activity is correlated to
increase in superoxide levels. Figure 5.2 displays the results of superoxide levels in
blood-brain barrier. Although superoxide levels were unchanged in HIV Tg group, ART
treated HIV group showed a significant (~6 fold) increase in superoxide levels (p<0.05).
Pretreatment with NACA decreased the superoxide levels to remarkably lower levels,
similar to that of control group (p<0.05). These results indicate NADPH oxidase enzyme
may be involved in the oxidative stress induced by ART drug in BBB.
5.2.5. Nitrite Levels in Brain after AZT+IDV Treatment. Activation of
NADPH oxidase enzyme results in an increase in the superoxide levels (O2·–). Superoxide
radicals react with nitric oxide (NO·), which gives rise to highly pro-oxidant peroxynitrite
(ONOO–). This compound triggers the formation of nitrotyrosine residues (Ntyr), which
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provides a tissue marker for reactive nitrogen-related tissue damage. Figure 5.3 displays
the increase in levels of nitrite in the brain samples of both HIV group as well as the ART
drug treated HIV group. The increases in the nitrite levels in both groups were
significantly different from control and the nitrite levels of brain were higher in ART
treated group than HIV transgenic animals. There was significant decrease in nitrite
levels of brain samples of NACA treated HIV+ART group. These results indicate the
involvement of a convergent mechanism in BBB dysfunction and also show that NACA
can alleviate some of the harmful effects of NADPH oxidase mediated injury.
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Table 5.1. GSH levels in BBB and Brain of HIV-Tg rats. (GSH: nmoles/mg of protein).
Results expressed as mean values (Mean±SEM; n=4). * Statistical differences (p<0.05)
as compared to untreated control, ** (p<0.05) compared to HIV treated group, # (p<0.05)
compared to HIV+ART treated group.

Groups

GSH
Brain microvessels

Whole brain

Control

5.7±0.6

15.1±1.6

NACA

3.2±0.5

16.4±5.0

HIV

1.6±0.1*

10.7±1.1*

HIV+NACA

2.2±0.1**

19.1±8.6

HIV+ART

0.9±0.1*

12.0±1.3*

HIV+ART+NACA

1.1±0.1

23.3±1.3#

71

Table 5.2. MDA levels in Brain of HIV-Tg rats. (MDA: nmoles/100mg of protein). *
Statistical differences (p<0.05) as compared to untreated control, ** (p<0.05) compared
to HIV treated group, # (p<0.05) compared to HIV+ART treated group (Mean±SEM;
n=4).
Groups

MDA

Control

67.0±3.7

NACA

55.9±2.6

HIV

78.1±3.8*

HIV+NACA

50.2±8.8**

HIV+ART

73.0±3.1*

HIV+ART+NACA

55.9±6.2#
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Fıgure 5.1. Effect of ART drugs and NACA on activity of NADPH oxidase. NADPH
oxidase activity was measured in the brain of HIV-Tg animals treated with ART
(AZT+IDV) drugs for 10 days. Animals in the NACA group pretreated with NACA 30
mins before ART drug injection. NADPH oxidase activity of the NACA alone and
HIV+NACA treated group similar to that of the control (data not shown). Data:
Mean±SEM; n=4. (*) indicates significantly different from the control, (!) significantly
different from the HIV+ART treated group.
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Fıgure 5.2. Effect of NACA on superoxide levels. Superoxide radical formation was
measured in the BBB in the brain of HIV-Tg animals treated with ART drugs
(AZT+IDV) drugs for 10 days. Animals in the NACA group pretreated with NACA 30
mins before ART drug injection. Superoxide radical formation of the NACA alone and
HIV+NACA treated group similar to that of the control. Data: Mean±SEM; n=4. (*)
indicates significantly different from the control, (!) significantly different from the
HIV+ART treated group.
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Fıgure 5.3. Effect of ART drugs and NACA on nitrite levels. Brain nitrite levels shown
above. Results expressed as average of mean values (Mean±SEM; n=2).
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6. DISCUSSION
6.1. IN VITRO RESULTS
The advent of HAART therapy has significantly revolutionized the treatment of
AIDS by increasing the lifespan of HIV-infected individuals, and creating a decline in
AIDS-related neurological disorders (Bell, 1998; Nath, 2002). Although HAART
treatment has reduced the prevalence of opportunistic infections like cytomegalovirus and
toxoplasmosis, the clinical impact of HAART toxicity on HIV-1-associated
neurocognitive disorders is still controversial (Krebs et al., 2000). Most of the clinical
studies report that cognitive impairment is still a significant clinical problem in HAARTtreated patients (Dore et al., 1999). Although several in vitro studies have shown that
HIV proteins and methamphetamine can cause dysfunction in the BBB, the effect of
HAART drugs on the BBB endothelial cells and its role in exacerbating HAND are not
yet known. In this study, we have used the combination of AZT and IDV, one of the most
commonly recommended HAART regimens, to elucidate their role in free radical
generation and mitochondrial dysfunction mediated endothelial cell death.
Here, we present evidence that HAART drugs are toxic to BBB endothelial cells
in a dose-dependent manner (Figure 4.1). We suggest that the high AZT and IDV
concentrations found to be active in our studies can be considered relevant. AZT + IDV
is used for the treatment of HIV-infected AIDS patients at doses of about 500–1500 mg
daily for a long survival period. The concentrations used in our experiments are achieved
at serum levels after oral administration (Collier et al., 2003). Endothelial cells exposed
to individual drugs showed that AZT was more toxic than IDV. AZT, a nucleoside
reverse transcriptase inhibitor, has been shown to decrease the levels of mitochondrial

76
DNA in vivo and clinically by inhibiting γ-DNA polymerase (Simpson et al., 1989; Lewis
et al., 1992). The decrease in mtDNA inhibits the synthesis of adequate proteins for
oxidative phosphorylation (OXPHOS). A subsequent energy loss and increase in
production of reactive oxygen species (ROS) has been reported in other studies involving
HAART treatment (Mondal et al., 2004). Our data concurs with those studies, as a
significant, concentration-dependent increase in total ROS was also observed in our
study, indicating an increase in the oxidative stress in response to the treatment (Figure
4.5).
One of the important effects of oxidative stress and free radical generation is
decreased levels of cellular antioxidants. GSH (γ-glutamyl-cysteinyl-glycine), a thiol
antioxidant in cells, is mainly responsible for maintaining cellular redox status in
endothelial cells. GSH scavenges free radicals and hydrogen peroxide, and neutralizes
toxic metabolites by condensing with them both enzymatically and nonenzymatically
(Meister, 1995). Long-term AZT treatment has been shown to induce oxidative damage
and deplete GSH in rats treated acutely and in cell cultures (Szabados et al., 1999). We
observed a dose-dependent decrease in GSH levels after HAART treatment suggesting
that AZT + IDV induced ROS production with subsequent decreases in GSH levels
(Figure 4.6). AZT + IDV may have caused an increase in levels of hydroperoxides that
exceeded the metabolic capabilities of the glutathione system to maintain glutathione in
the reduced form. In fact, mitochondria are highly dependent on glutathione to detoxify
ROS and prevent oxidative damage (Lewis et al., 1995).
A decrease in GSH and an increase in ROS set off a cascade of further oxidative
damage. An important target of oxidative damage is brain microvessel endothelial cells
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because they are rich in polyunsaturated fatty acids (PUFAs). ROS attacks double bonds
in PUFAs, thereby degrading the lipids and generating MDA as by product. MDA is a
widely used oxidative stress parameter, reacting with deoxyadenosine and
deoxyguanosine to form mutagenic DNA adducts (Marnett, 1999). Studies have shown
that AZT treated mice have higher levels of plasma MDA, as compared to control mice
(Garcia et al., 2007).Our results also indicated that AZT + IDV treatment increased the
levels of lipid peroxidation metabolites because of oxidative damage (Fig. 4.7).
The predominant enzymatic mechanisms that regulate intracellular H2O2 levels
are mediated by catalase and glutathione peroxidase. In the current study, catalase
activity of hCMEC/D3cells after exposure to AZT+IDV was measured by following the
disappearance of H2O2. As indicated in figure (4.8), a dose dependent decrease in catalase
activity was seen after 72 hr exposure to AZT+IDV. The ability of AZT+IDV to reduce
catalase activity has been shown before in other models, such as the human umbilical
endothelial cell line, HUVEC. Transduction with the mitochondria-targeted catalase
(mCAT) was more effective than cytoplasmic catalase in inhibiting the ROS and 8isoprostane (8-iso-PGF2alpha) produced after treatment with either AZT or indinavir
(Jiang et al., 2007). Similarly transgenic animals overexpressing mCAT treated with AZT
were protected from cardiac dysfunction (Kohler et al., 2009). It is so far poorly
understood through which mechanisms AZT and IDV affect the function of catalase.
However it is thought that tyrosyl radical in catalase enzyme is involved in the in the
catalytic activity of the enzyme (Ivancich et al., 1997; Chouchane et al, 2002). Nitration
or reaction of free radicals with this tyrosine residue could lead to inactivation of the
enzyme. Other studies have reported that phosphorylation of the tyrosine residue on
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catalase may lead to decreased activity of catalase enzyme (Zhang et al., 2005; Suarez et
al., 2009).
Mitochondria are logical targets for oxidative stress, based on their ability to
generate free radicals, and may be primarily involved in oxidative stress associated with
AIDS treatment. Under physiological conditions, reactive oxygen species (ROS) are
produced mainly by the mitochondria during OXPHOS, as electrons travel through the
electron transport chain (ETC). During OXPHOS, electrons leak out of the ETC and
result in the formation of superoxide instead of water. Superoxide is generated at
complex I (NADH dehydrognase) and complex III (ubiquinone Q-cytochrome b). Any
alteration in redox status of these complexes results in an excessive production of
superoxide radical (Boveris et al., 1973). Mitochondrial hydrogen peroxide is also rapidly
formed from superoxide by dismutation or by mitochondrial manganese superoxide
dismutase. Hydroxyl radicals are known to form at sites where superoxide and hydrogen
peroxide are formed in mitochondria (Taylor et al., 1995). The free radicals generated can
act on mitochondrial proteins, lipids, and even mtDNA, thereby altering the
electrochemical gradient across the mitochondria resulting in mitochondrial dysfunction
(Lin et al., 2006). An electrochemical gradient across mitochondrial inner membrane or
mitochondrial membrane potential (ΔΨm) is important for mitochondrial electron
transport and energy metabolism. A decrease in ΔΨm after treatment was detected and
assessed in our studies by using fluorescent microscopy. In addition to this, we also
observed a dose-dependent decrease in ATP levels after treatment. Loss of ΔΨm
interferes with the production of ATP, the cell's main source of energy, because
mitochondria must have an electrochemical gradient to provide the driving force for ATP
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production. Decreases in ΔΨm and ATP levels seen in our study are consistent with
disrupted mitochondrial function.
To determine the oxidative stress effect of AZT+IDV, the expression of MnSOD
expression was evaluated. Results from 50 µM indeed support the fact, as seen by
increased expression of MnSOD. In support to our results, various other studies have
reported that a mild to moderate increase in oxidative stress increased MnSOD
expression in various cell types (Li et al., 2010; Liu et al., 2010). Higher or
overwhelming oxidative stress tends to decrease the expression of MnSOD levels as seen
from results in 200 µM treated groups (Chaudauri et al., 2010).
Reactive oxygen and nitrogen species, decreased mitochondrial membrane
potential, and oxidation of pyridine nucleotides and glutathione all promote
mitochondrial damage and the onset of a phenomenon known as mitochondrial
permeability transition (MPT). MPT is a sudden increase in the permeability of the inner
mitochondrial membrane, loss of ΔΨm, uncoupling of oxidative phosphorylation,
mitochondrial swelling, and the release of intramitochondrial ions through the
mitochondrial membrane transition pore (MPTP) (Lemasters et al., 1998). Mitochondrial
permeability transition (MPT), is recognized as an initiating phenomenon, important for
both necrosis and apoptosis (Lemasters et al., 1998). Swelling of the mitochondria due to
increased permeability ruptures the outer membrane of the mitochondria releasing the
cytochrome c into the cytoplasm. Cytochrome c can, in turn, cause apoptosis of cells by
activating pro-apoptotic factors (Skulachev, 1998). Endothelial cell apoptosis has been
demonstrated in an atherosclerotic lesion and has been considered a mechanism for
atherogensis in HAART-treated patients (Barbaro et al., 2006). AZT treatment has
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induced apoptosis in placental cells and parathyroid cancer cells (Falchetti et al., 2005).
Contrary to these and various other studies, AZT + IDV did not induce apoptosis at
therapeutic concentrations in primary human umbilical cells and various other studies
(Jiang et al., 2007). In addition to this, an emerging body of literature suggests that
protease inhibitors may also be anti-apoptotic by inhibiting calpain (Lichtner et al.,
2006). In view of this conflicting research, we tested whether AZT + IDV can induce
apoptosis in hCMEC/D3 cells. Cytchrome c and procaspase 3 levels were elevated in
cytosolic fractions of the treated groups when compared to those of the control groups.
To further ascertain that AZT + IDV treatment induced apoptosis, cells stained with an
AO/EB mixture were observed under a fluorescent microscope. Treated cells showed
changes in cellular morphology, including chromatin condensation, membrane blebbing,
and fragmented nuclei and apoptotic bodies. Results from both studies provided sufficient
support that AZT + IDV treated hCMEC/D3 cells were undergoing programmed cell
death.
Apoptosis can be triggered by many different stimuli, including engagement of
death receptors by cytokines (such as TNF-alpha and Fas ligand), toxins, and oxidative
stress. Early events in apoptosis include the release of cytochrome c (from mitochondria)
and calcium from endoplasmic reticulum in to the cytosol, which are necessary for
apoptosis. A small amount of cytochrome c released from mitochondria can bind to and
promote calcium conductance through inositol-1,4,5–triphosphate (InsP3) receptors in the
endoplasmic reticulum membrane. The released calcium then triggers a massive exodus
of cytochrome c from all mitochondria in the cell, thereby activating the caspases and
nuclease enzymes that finalize the apoptotic process (Boehning et al., 2003). Evidently,
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calcium uptake into the mitochondria is secondary to an increase in the cytoplasmic
calcium concentration as a stimulus for the massive release of cytochrome c. Results
from our studies show that a calcium based mechanism may be involved in the extensive
release of cytochrome c and the execution of cell death induced by an AZT + IDV
combination in blood-brain vascular endothelial cells.
A noticeable decrease in trans-endothelial electrical resistance (TEER) and an
increase in dextran permeability across the monolayer of endothelial cells provide
evidence that HAART drugs induce gaps between endothelial cells. This is in agreement
with results reported from previous studies (Fiala et al., 2000). Inflammatory mediators
(histamine and thrombin) tend to increase centripetal tension and intercellular and matrix
adhesion in the absence of a rise in cyclic adenine monophosphate. Thrombin triggers
multiple signal pathways through activation of G proteins which can, in turn, activate
phospholipase C. Activation leads to a series of signaling cascades, ultimately leading to
protein kinase C activation. These signals lead to activation of multiple protein kinases
and phosphorlyation of their target proteins, filamin, myosin light chain kinase (MLCK),
and tight junction (TJ) proteins (Sansdoval et al., 2001). Phosphorylation of these target
proteins induces interendothelial gaps and monocyte migration across the BBB models
(Bogatcheve et al., 2002). Our data concurs with a previous study on endothelial cells,
which showed that HAART drugs can induce gaps between endothelial cells.
Glutathione (L-γ-glutamyl-L-cysteinylglycine, GSH) is the most prevalent intracellular thiol in mammals. It is known to be involved either directly or indirectly in a
number of biological phenomena, including protecting cells from harmful reactive
oxygen intermediates (ROI), and acting as a coenzyme in several enzyme catalyzed
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reactions. Although GSH by itself is poorly absorbed through cells and has high affinity
for oxidation, various analogues of cysteine and GSH have been synthesized known to
easily permeate cell. One such kind of analogue known to pass BBB and increase GSH
levels is N-acetylcysteine amide (NACA). Although cytotoxicity in AZT+IDV treated
cells was abolished, a slight increase in viability was observed in cells pretreated with
NACA.
In order to comprehend the results, and further establish the antioxidant effects of
NACA, the ROS levels in treated cells were evaluated. NACA completely decreased the
ROS levels in the AZT+IDV treated group. These results agree with data reported from
previous other studies, where NACA successfully inhibited the increase in free radicals
(Penugonda et al., 2005) NACA is thought to increase GSH levels in cells, both by
providing the important GSH precursor cysteine, and by reducing GSSG back to GSH by
thiol disulfide exchange (Grinberg et al., 2005). According to figure 4.20 NACA
appears, to replenish GSH levels, which may be useful in reversing some of deleterious
effect of oxidative insults.
The ability of NACA to scavenge ROS and increase GSH levels without a
significant effect on cell viability, as seen in our studies, has also been reported in
previously reported studies of NACA (Rong et al., 2009). Moreover cells were only
preinucbated with NACA in our studies for only 1 hr prior to 72 hr exposure with
AZT+IDV. Further research needs to be done to develop an effective dosing protocol to
efficiently establish the effects of NACA.
In summary, our results demonstrate that the HAART drug combination of AZT +
IDV can induce cytotoxicity and alter the blood-brain endothelial cell functions.
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Alteration of the endothelial functions is due to increased oxidative stress and lipid
peroxidation. Our results also suggest that treatment with AZT + IDV leads to
depolarization of membrane potential and energy loss, ultimately causing mitochondrial
dysfunction. Furthermore, treated cells undergoing apoptosis and elevated intracellular
calcium mediated the drug-induced apoptosis in our current study. Thus, treatment with
HAART drug combinations may have to be used with caution in HIV-infected patients,
although inclusion of antioxidants like NACA in HAART therapy may protect patients
with HIV-1 associated neurocognitive disorders from drug-induced toxicity.
6.2. IN VIVO RESULTS
Vascular function is as essential as the heart beat, since it regulates blood pressure
and thereby protects from hypertension and atherosclerosis in the long term. In addition,
it maintains the function of the vessel walls as a blood-barrier in the brain and thereby
prevents leukocyte infiltration as well as inflammatory processes in the vascular wall.
Blood-brain barrier disruption has been implicated in numerous neurocognitive disorders.
The role of HAART drugs in BBB disruption and the mechanism involved in this
disruption is poorly understood in HAND. Our previous in vitro study with HAART
drugs proved that AZT + IDV induced toxicity through an oxidative stress mediated
mechanism in cell model of the BBB. Pretreatment with NACA abrogated some of the
effects due to drug exposure in in vitro study. In addidition, an in vivo study was
conducted to further understand the mechanism and implicate the oxidative stress role of
HAART drugs in BBB disruption, and also to establish the protective role of thiol
antioxidant NACA to protect against oxidative stress in HIV transgenic animals treated
with HAART drugs.
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Initially to elucidate the oxidative stress effect of viral proteins and antiretroviral
drugs in the BBB and brain, GSH levels were measured in BBB microvessels as well as
in the brain (Table 5.1). In the literature, a decrease in GSH levels has been connected to
physiological processes such as aging and neurological disorders like schizophrenia,
Alzheimer's disease, and epilepsy (Do et al., 2000; Gu et al., 1998; Mueller et al., 2001).
Previous studies from our lab have reported that animals exposed to HIV viral proteins
(gp120+Tat) had significant decreases in GSH levels in their brains as compared to
controls. In our study we report similar results in the brain as well as the BBB, which
indicate that viral proteins decrease GSH (Banerjee et al., 2010). The decrease in GSH is
attributed to increase in oxidative stress in cell culture and in in vivo settings as well.
Along with that, treatment with ART drugs also decrease GSH in the BBB and the brain.
This result advocates our findings obtained in BBB cell model. NACA treatment in these
animals replenished the thiol levels in both HIV and HIV+ART group. Decreased GSH
may increase the susceptibility to free radical attack of cellular proteins and lipids
resulting in MDA, an end product of lipid peroxidation. Our results in both the HIV and
HIV group treated with ART drugs show an increase in MDA levels. Pretreatment with
NACA decreased the levels of MDA in both the HIV and HIV+ART groups.
Various effects of HIV neuropathology in HAART-medicated patients have been
reported, including severe white matter injury, extensive perivascular lymphocytic
infiltration, and Aβ accumulation of AD-like lesions (Gray et al., 2003, 2005; Greene et
al., 2005). Recent studies suggest that HAND prevalence is actually rising as the number
of treated subjects with chronic HIV infection increases, despite HAART medication (Xu
et al., 2009). Consequently, considering the link between chronic neuroinflammation,

85

neuronal/ synaptodenritic degeneration and Alzheimers disease, neuroinflammation is
likely to play an important role in the pathogenesis of HAND by the killing of neurons
through inflammatory mechanisms. ROS play a key role in inflammatory tissue
destruction. The phagocyte NADPH oxidase is the best studied ROS-generating system.
In the central nervous system, it is expressed in microglia in the brain and to a lesser
extent in neurons. Indeed, there is emerging experimental evidence for a role of NADPH
oxidase in Alzheimer's and cerebrovascular disease. Recently, six novel ROS-generating
NADPH oxidases have been discovered (Sankarpandi et al., 1998; Bianca et al., 1999).
Several of them are also expressed in the central nervous system. In this current study, we
hypothesize a role of NADPH oxidases in neurocognitive disorders in HAART treated
patients.
In addition to mitochondrial sources of ROS, O2·–can be derived from xanthine
oxidase, NADPH oxidases, cyclooxygenases, lipoxygenases and uncoupled nitric oxide
synthase. On the basis of experimental and clinical studies it has been proposed that
NADPH oxidase is the predominant, O2·– producing enzyme in the context of oxidative
stress. NADPH oxidase activation has also been implicated in loss of neuronal coupling.
According to figure 5.1 NADPH oxidase activities in both the HIV and ARTtreated group appear to be elevated, with the latter showing a higher activity than former
HIV group. To best of our knowledge we are the first to report the increase in NADPH
oxidase activity in brain samples of ART treated HIV transgenic animals. NADPH
oxidase activation has been also implicated in disruption of blood brain barrier following
stroke and in apoptosis (Kahles et al., 2007). Administration of NACA appears to have
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alleviated some of the NADPH oxidase activity. Although the specific inhibitory
mechanism involved cannot be explained at this juncture.
Activation of NADPH oxidase enzyme results in transport of electrons from
NADPH to molecular oxygen resulting in formation of superoxide. In order to support
our earlier assumption and results of NADPH oxidase activation, we measured the
superoxide levels. Although the HIV treated group did not show any increase in O2·–
when compared to control, ART treated HIV group showed a massive increase in O2·–
levels. Studies with ritonavir showed an increased NADPH oxidase activity in porcine
arteries (Chai et al., 2005). Wang et al have shown that superoxide anion is significantly
increased in porcine coronory arteries treated with ritonavir and amprenavir.
Furthermore, they showed that indinavir and AZT- treated porcine arteries also had a
significant increase in superoxide levels when compared to control (Wang et al., 2009;
Jiang et al., 2010). Treatment with NACA decreased the superoxide levels in the ART
treated HIV group (Figure 5.2). This effect can be explained based on the thiol group (SH) group in NACA. Thiols react with free radicals by quenching the free radicals and,
in turn losing proton forming thiyl radicals, which undergo a self-quenching process by
forming a disulfide bond.
NADPH oxidase-derived superoxide reacts with NO. to form peroxynitrite
(ONOO-) that is toxic. The highly reactive peroxynitrite has been implicated in the death
of cultured neurons and oligodendrocyte progenitors (Scott et al., 2003). Tyrosine
nitration, a marker of ONOO- activity, has been correlated with tissue damages in human
neuropathologies such as multiple sclerosis, ALS, and Parkinson’s and Alzheimer’s
diseases, as well as in animal models of these diseases, including LPS-triggered
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neuroinflammation (Cheret et al., 2008). Our results (shown in Figure 5.3) indicate an
increase in the levels of nitrite formation in ART treated HIV group as a result of higher
superoxide levels generation mediated by NADPH oxidase. It is also interesting that the
ART treated group had a greater increase in nitrite levels when compared HIV groups
indicating that ART may be potentiating NADPH oxidase activity in HIV transgenic
animals. Treatment with NACA significantly reduced the nitrite levels in ART +HIV
group. Peroxynitrite reacts with the thiol group producing the unstable sulphenic acid,
which in turn reacts with another thiol yielding the disulphide by a two electron oxidation
pathway. One-electron oxidation pathway is also believed involved in reducing
peroxynitrite levels. Peroxynitrous acid, or a secondary species derived from it, reacts
with the thiol producing the thiyl radical. The latter can dimerize to the disulphide, or can
react with oxygen to produce the peroxyl radical or with the thiolate yielding the
disulphide radical anion (Quijano et al., 1997).
A proposed convergent mechanism based upon our in vitro and in vivo results,
involved in blood-brain endothelial dysfunction as illustrated in Figure 6.1. HAART
drugs may induce oxidative stress and mitochondrial dysfunction by increasing reactive
oxygen species. These ROS may, in turn cause a decrease in GSH and increase in an
MDA levels. Changes in these parameters may also result in apoptosis and endothelial
dysfunction. It is also possible that HAART drugs may activate NADPH oxidase enzyme,
thereby increasing superoxide production, which, in turn may lead to peroxynitrite radical
generation. Nitration of proteins and enzymes by ONOO- may lead to further deleterious
signaling cascade, resulting in BBB endothelial dysfunction and neurodegeneration in the
brain and neurocognitive disorders in HAART- treated HIV subjects.
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Figure 6.1. Schematic illustration of proposed mechanism for BBB dysfunction.
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7. CONCLUSION
HIV-1 associated neurocognitive disorders are a still a significant health concern
in HIV patients treated with antiretroviral therapy. Although HAART treatment has
resulted in decreased mortality, the negative impact of therapy resulted in endothelial
dysfunction related disorders like cardiovascular diseases. However, their effect on BBB
and brain has not been studied in relation to neurocognitive disorders. Our study
attempted to evaluate the effect of an antiretroviral drug combination of AZT and IDV on
the BBB and brain.
Findings from our in vitro studies with HAART drugs (AZT+IDV) indicate that
prolonged use of antiretroviral drugs may alter the function of the BBB. These potential
toxic effects appear to be manifested through the dysfunction of the mitochondria and
increase in oxidative stress. Our results from in vivo studies demonstrate that an alternate
pathway involving reactive nitrogen species (RNS) may take part in signaling cascade of
BBB disruption and neuronal degeneration in the brain. The protective effects of NACA
were also shown in reducing the oxidative stress mediated effects of the AZT and IDV
combination. The antioxidant effects of NACA against RNS were also prominent in
ART -treated HIV transgenic rats. The increases in oxidative stress and NADPH oxidase
activity in the BBB and brain is of particular concern in ART- treated groups and may
signify their ability to potentiate the degenerative effect of viral proteins. No
neurodegenerative markers were studied in this part of research, so the role of ART drugs
in HAND is still unclear and needs further in depth investigation. The inclusion of thiol
antioxidants like NACA, with the ability to cross the BBB, may prove beneficial in
delaying or inhibiting some of the symptoms of neurocognitive disorder.
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